Use of aryl and hetaryl carboxamides as endoparasiticides

ABSTRACT

The present application relates to known and novel aryl- and hetarylcarboxamides of the formula (I) 
     
       
         
         
             
             
         
       
     
     and to their use as medicaments for controlling endoparasites in animals or humans, and also to parasiticidal compositions, in particular endoparasites, comprising aryl- and hetarylcyclylcarboxamides.

The present application relates to known and novel aryl- and hetarylcarboxamides and their use as parasiticides for endoparasites in animals or humans, and also to parasiticides, in particular endoparasitices, comprising the aryl- and hetarylcarboxamides.

In the field of veterinary medicine, the occurrence of resistances against all commercially available anthelmintics is an increasing problem which requires endoparasiticides having novel molecular mechanisms of action. Such compounds should exhibit excellent efficacy against a broad spectrum of helminths and nematodes and at the same time not cause any toxic effects in the animals treated. Endoparasiticidal compositions are medicaments used for controlling endoparasites in humans and animals.

WO-A 2001/060783 claims certain phenacylbenzamides for oral use as anthelmintics in veterinary medicine.

Isothiazolecarboxamides are known from WO-A 1999/24413, heterocyclylethylcarboxamide derivatives from WO-A 2006/108791, heterocyclylethylbenzamide derivatives from WO-A 2006/108792, N-(1-methyl-2-phenylethyl)benzamides from WO-A 2007/060162, N-(1-methyl-2-phenylethyl)carboxamides from WO-A 2007060164, N-phenethylcarboxamide derivatives from WO-A 2007/060166, N-(3-phenylpropyl)carboxamides from WO-A 2008/101976, pyrazolecarboxamides from WO-A 2008/148570 and WO-A 2010/063700, pyrazinylcarboxamides from WO-A 2011/128989, and also various 2-pyridylethylcarboxamide derivatives from WO-A 2004/016088, WO-A 2004/074280, WO-A 2005/014545, WO-A 2005/058828, WO-A 2005/058833 and WO-A 2005/085238 as agrochemical fungicides. Furthermore, WO-A 2007/108483 describes N-2-(hetero)arylethylcarboxamide derivatives as fungicides and nematicides. WO-A 2008/126922 explicitly claims the use of 2-pyridylethylcarboxamide derivatives for use against nematodes in crop cultivation.

The use of these (het)arylethyl- or (het)arylpropylcarboxamides as endoparasiticides in veterinary medicine has hitherto not been described.

It has now been found that compounds of the formula (I)

in which

-   X represents mono- or poly-M¹-substituted phenyl, thienyl or     furanyl; -   Q represents mono- or poly-M¹-substituted phenyl, pyridyl, thienyl,     furanyl or isothiazolyl; -   Y represents hydrogen or represents optionally mono- or     poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl,     (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl,     (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₂-C₁₀)-alkenyloxy,     (C₃-C₁₀)-alkynyloxy, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or     represents an optionally mono- or poly-M²-substituted 3- to     14-membered cyclic group; -   W represents oxygen or sulfur; -   L¹ represents —C(R¹¹, R¹²)—, oxygen, sulfur or —N(R¹)—; -   L² represents —C(R²¹, R²²)—; -   L³ represents —C(R³¹, R³²)— or a direct bond; -   M¹ represents hydrogen, halogen, cyano, nitro, OH, (C₁-C₁₀)-alkyl,     (C₁-C₁₀)-haloalkyl, (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-haloalkoxy,     (C₁-C₁₀)-alkylthio, (C₁-C₁₀)-haloalkylthio, (C₁-C₁₀)-alkylsulfonyl,     (C₁-C₁₀)-haloalkylsulfonyl, (C₁-C₁₀)-alkylsulfanyl,     (C₁-C₁₀)-haloalkylsulfanyl, (3- to 14-membered cyclic group)-O—; -   R¹ represent hydrogen or optionally mono- or poly-M²-substituted     (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl,     (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl,     (C₃-C₁₀)-cycloalkyl-(C₁-C₁₀)-alkyl or represents an optionally mono-     or poly-M²-substituted 3- to 14-membered cyclic group; -   R¹¹, R¹² each independently of one another represent hydrogen,     halogen or optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl,     (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl,     (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy,     (C₂-C₁₀)-alkenyloxy, (C₃-C₁₀)-alkynyloxy,     (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represents an optionally mono-     or poly-M²-substituted 3- to 14-membered cyclic group; -   R¹¹, R¹² together represent an optionally mono- or     poly-M²-substituted spiro-attached 3- to 14-membered carbo- or 3- to     10-membered heterocyclic group; -   R²¹, R²² each independently of one another represent hydrogen,     halogen or optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl,     (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl,     (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy,     (C₁-C₁₀)-haloalkoxy, (C₂-C₁₀)-alkenyloxy, (C₃-C₁₀)-alkynyloxy,     (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represent an optionally mono-     or poly-M²-substituted 3- to 14-membered cyclic group; -   R²¹, R²² together represent an optionally mono- or     poly-M²-substituted spiro-attached 3- to 14-membered carbo- or 3- to     10-membered heterocyclic group; -   R³¹, R³² each independently of one another represent hydrogen or     optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl,     (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl,     (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl,     (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represent an optionally mono-     or poly-M²-substituted 3- to 14-membered cyclic group; -   R³¹, R³² together represent an optionally mono- or     poly-M²-substituted spiro-attached 3- to 14-membered carbo- or 3- to     10-membered heterocyclic group; -   M² each independently of one another represent halogen, formyl,     cyano, nitro, (C₁-C₁₀)-alkyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-alkenyl,     (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-alkynyl, (C₂-C₁₀)-haloalkynyl,     (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-haloalkoxy, (C₂-C₁₀)-alkenyloxy,     (C₂-C₁₀)-haloalkenyloxy, (C₃-C₁₀)-alkynyloxy,     (C₃-C₁₀)-haloalkynyloxy, (C₁-C₁₀)-alkylthio, (C₁-C₁₀)-haloalkylthio,     (C₂-C₁₀)-alkenylthio, (C₂-C₁₀)-haloalkenylthio,     (C₃-C₁₀)-alkynylthio, (C₃-C₁₀)-haloalkynylthio,     (C₁-C₁₀)-alkylsulfonyl, (C₁-C₁₀)-haloalkylsulfonyl,     (C₂-C₁₀)-alkenylsulfonyl, (C₂-C₁₀)-haloalkenylsulfonyl,     (C₃-C₁₀)-alkynylsulfonyl, (C₃-C₁₀)-haloalkynylsulfonyl,     (C₁-C₁₀)-alkylsulfanyl, (C₁-C₁₀)-haloalkylsulfanyl,     (C₂-C₁₀)-alkenylsulfanyl, (C₂-C₁₀)-haloalkenylsulfanyl,     (C₃-C₁₀)-alkynylsulfanyl, (C₃-C₁₀)-haloalkynylsulfanyl,     (C₁-C₁₀)-alkylcarbonyl, (C₁-C₁₀)-haloalkylcarbonyl,     (C₂-C₁₀)-alkenylcarbonyl, (C₂-C₁₀)-haloalkenylcarbonyl,     (C₂-C₁₀)-alkynylcarbonyl, (C₂-C₁₀)-haloalkynylcarbonyl,     (C₁-C₁₀)-alkoxycarbonyl, (C₁-C₁₀)-haloalkoxycarbonyl,     (C₂-C₁₀)-alkenyloxycarbonyl, (C₂-C₁₀)-haloalkenyloxycarbonyl,     (C₃-C₁₀)-alkynyloxycarbonyl, (C₃-C₁₀)-haloalkynyloxycarbonyl,     (C₁-C₁₀)-alkylcarbonyloxy, (C₁-C₁₀)-haloalkylcarbonyloxy,     (C₂-C₁₀)-alkenylcarbonyloxy, (C₂-C₁₀)-haloalkenylcarbonyloxy,     (C₂-C₁₀)-alkynylcarbonyloxy, (C₂-C₁₀)-haloalkynylcarbonyloxy, a 3-     to 14-membered cyclic group;     and salts, N-oxides and tautomeric forms of the compounds of the     formula (I);     are used as medicaments in animals or humans, in particular for     endoparasites.

The compounds of the formula (I) may, where appropriate, depending on the nature of the substituents, be in the form of geometric and/or optically active isomers or corresponding isomer mixtures of varying composition. The invention relates both to the pure isomers and to the isomer mixtures.

The compounds according to the invention can also be present as metal complexes.

DEFINITIONS

The term animals does not include humans.

The term “mono- or poly-” means preferably mono- to hexa-, particularly preferably mono- to tetra-, very particularly preferably mono- to tri- and especially preferably mono- or di-.

The person skilled in the art is aware that the expressions “a” or “an” as used in the present application may, depending on the situation, mean “one (1)”, “one (1) or more” or “at least one (1)”.

For all ring systems hitherto described, adjacent atoms must not be —O—O— or —O—S—.

For the sake of simplicity, structures having a variable number of possible carbon atoms (C atoms) are referred to as C₁-C₁₀-structures (C₁-C₁₀) in the present application. Example: an alkyl group of 1 to 10 carbon atoms corresponds to (C₁-C₁₀)-alkyl. Ring structures of carbon atoms and heteroatoms are referred to as “3- to 14-membered” structures.

If a collective term for a substituent, for example (C₁-C₁₀)-alkyl, is at the end of a composite substituent such as, for example, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl, the component at the end of the composite substituent, for example the (C₁-C₁₀)-alkyl, may be mono- or polysubstituted by identical or different substituents and independently of the substituent at the beginning, for example (C₃-C₁₄)-cycloalkyl.

Unless defined differently, the definition for collective terms also applies to these collective terms in composite substituents. Example: The definition of (C₁-C₁₀)-alkyl also applies to (C₁-C₁₀)-alkyl as component of a composite substituent such as, for example, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl.

It is obvious to the person skilled in the art that the examples given in the present application are not to be considered as limiting, but rather describe some embodiments in more detail.

In the definitions of the symbols given in the formulae above, collective terms were used which are generally representative of the following substituents:

Collective Terms

Halogen, unless defined otherwise: elements of the 7th main group; preference is given to fluorine, chlorine, bromine and iodine.

(C₁-C₁₀)-Alkyl, unless defined differently elsewhere: saturated straight-chain or branched hydrocarbon radicals having preferably (C₁-C₆)—, particularly preferably (C₁-C₄)-carbon atoms. Examples: methyl, ethyl, isopropyl, n-propyl, 1-methylethyl, butyl, tert-butyl, etc.

(C₂-C₁₀)-Alkenyl, unless defined differently elsewhere: unsaturated straight-chain or branched hydrocarbon radicals having a double bond. Preference is given to (C₂-C₆)- or (C₂-C₄)-alkenyl. Examples: ethenyl, 1-propenyl, 3-butenyl, etc.

(C₂-C₁₀)-Alkynyl, unless defined differently elsewhere: unsaturated straight-chain or branched hydrocarbon radicals having a triple bond. Preference is given to (C₂-C₆)- or (C₂-C₄)-alkynyl. Examples: ethynyl, 1-propynyl, etc.

(C₁-C₁₀)-Alkoxy (alkyl radical-O—), unless defined differently elsewhere: an alkyl radical which is attached to the skeleton via an oxygen atom (—O—). Preference is given to (C₁-C₆)- or (C₁-C₄)-alkoxy. Examples: methoxy, ethoxy, propoxy, 1-methylethoxy, etc.

Analogously, (C₂-C₁₀)-alkenyloxy and (C₃-C₁₀)-alkynyloxy, unless defined differently elsewhere, are alkenyl radicals and alkynyl radicals, respectively, which are attached to the skeleton via —O—. Preference is given to (C₂-C₆)- or (C₂-C₄)-alkenyloxy. Preference is given to (C₃-C₆)- or (C₃-C₄)-alkynyloxy.

(C₁-C₁₀)-Alkylcarbonyl (alkyl radical-C(═O)—), unless defined differently elsewhere: preference is given to (C₁-C₆)- or (C₁-C₄)-alkylcarbonyl. Here, the number of the carbon atoms refers to the alkyl radical in the alkylcarbonyl group.

Analogously, (C₂-C₁₀)-alkenylcarbonyl and (C₂-C₁₀)-alkynylcarbonyl, unless defined differently elsewhere, are: alkenyl radicals and alkynyl radicals, respectively, which are attached to the skeleton via —C(═O)—. Preference is given to (C₂-C₆)- or (C₂-C₄)-alkenylcarbonyl. Preference is given to (C₂-C₆)- or (C₂-C₄)-alkynylcarbonyl.

(C₁-C₁₀)-Alkoxycarbonyl (alkyl radical-O—C(═O)—), unless defined differently elsewhere: preference is given to (C₁-C₆)- or (C₁-C₄)-alkoxycarbonyl. Here, the number of the carbon atoms refers to the alkyl radical in the alkoxycarbonyl group.

Analogously, (C₂-C₁₀)-alkenyloxycarbonyl and (C₃-C₁₀)-alkynyloxycarbonyl, unless defined differently elsewhere, are: alkenyl radicals and alkynyl radicals, respectively, which are attached to the skeleton via —O—C(═O)—. Preference is given to (C₂-C₆)- or (C₂-C₄)-alkenyloxycarbonyl. Preference is given to (C₃-C₆)- or (C₃-C₄)-alkynyloxycarbonyl.

(C₁-C₁₀)-Alkylcarbonyloxy (alkyl radical-C(═O)—O—), unless defined differently elsewhere: an alkyl radical which is attached to the skeleton via a carbonyloxy group (—C(═O)—O—) with the oxygen. Preference is given to (C₁-C₆)- or (C₁-C₄)-alkylcarbonyloxy.

Analogously, (C₂-C₁₀)-alkenylcarbonyloxy and (C₂-C₁₀)-alkynylcarbonyloxy, unless defined differently elsewhere, are: alkenyl radicals and alkynyl radicals, respectively, which are attached to the skeleton via (—C(═O)—O—). Preference is given to (C₂-C₆)- or (C₂-C₄)-alkenylcarbonyloxy. Preference is given to (C₂-C₆)- or (C₂-C₄)-alkynylcarbonyloxy.

(C₁-C₁₀)-Alkylthio, unless defined differently elsewhere: an alkyl radical which is attached to the skeleton via —S—. Preference is given to (C₁-C₆)- or (C₁-C₄)-alkylthio.

Analogously, (C₂-C₁₀)-alkenylthio and (C₃-C₁₀)-alkynylthio, unless defined differently elsewhere, are: alkenyl radicals and alkynyl radicals, respectively, which are attached to the skeleton via —S—. Preference is given to (C₂-C₆)- or (C₂-C₄)-alkenylthio. Preference is given to (C₃-C₆)- or (C₃-C₄)-alkynylthio.

(C₁-C₁₀)-Alkylsulfinyl, unless defined differently elsewhere: an alkyl radical which is attached to the skeleton via —S(═O)—. Preference is given to (C₁-C₆)- or (C₁-C₄)-alkylsulfinyl.

Analogously, (C₂-C₁₀)-alkenylsulfinyl and (C₃-C₁₀)-alkynylsulfinyl, unless defined differently elsewhere, are: alkenyl radicals and alkynyl radicals, respectively, which are attached to the skeleton via —S(═O)—. Preference is given to (C₂-C₆)- or (C₂-C₄)-alkenylsulfinyl. Preference is given to (C₃-C₆)- or (C₃-C₄)-alkynylsulfinyl.

(C₁-C₁₀)-Alkylsulfonyl, unless defined differently elsewhere: an alkyl radical which is attached to the skeleton via —S(═O)₂—. Preference is given to (C₁-C₆)- or (C₁-C₄)-alkylsulfonyl.

Analogously, (C₂-C₁₀)-alkenylsulfonyl and (C₃-C₁₀)-alkynylsulfonyl, unless defined differently elsewhere, are: alkenyl radicals and alkynyl radicals, respectively, which are attached to the skeleton via —S(═O)₂—. Preference is given to (C₂-C₆)- or (C₂-C₄)-alkenylsulfonyl. Preference is given to (C₃-C₆)- or (C₃-C₄)-alkynylsulfonyl.

(C₁-C₁₀)-Haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-haloalkoxy, (C₂-C₁₀)-haloalkenyloxy, (C₃-C₁₀)-haloalkynyloxy, (C₁-C₁₀)-haloalkylcarbonyl, (C₂-C₁₀)-haloalkenylcarbonyl, (C₂-C₁₀)-haloalkynylcarbonyl, (C₁-C₁₀)-haloalkoxycarbonyl, (C₂-C₁₀)-haloalkenyloxycarbonyl, (C₃-C₁₀)-haloalkynyloxycarbonyl, (C₂-C₁₀)-haloalkylcarbonyloxy, (C₂-C₁₀)-haloalkenylcarbonyloxy, (C₂-C₁₀)-haloalkynylcarbonyloxy, (C₁-C₁₀)-haloalkylthio, (C₂-C₁₀)-haloalkenylthio, (C₃-C₁₀)-haloalkynylthio, (C₁-C₁₀)-haloalkylsulfinyl, (C₂-C₁₀)-haloalkenylsulfinyl, (C₃-C₁₀)-haloalkynylsulfinyl, (C₁-C₁₀)-haloalkylsulfonyl, (C₂-C₁₀)-haloalkenylsulfonyl, (C₃-C₁₀)-haloalkynylsulfonyl are, unless defined differently, defined analogously to (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-alkoxy, (C₂-C₁₀)-alkenyloxy, (C₃-C₁₀)-alkynyloxy, (C₁-C₁₀)-alkylcarbonyl, (C₂-C₁₀)-alkenylcarbonyl, (C₂-C₁₀)-alkynylcarbonyl, (C₁-C₁₀)-alkoxycarbonyl, (C₂-C₁₀)-alkenyloxycarbonyl, (C₃-C₁₀)-alkynyloxycarbonyl, (C₁-C₁₀)-alkylcarbonyloxy, (C₂-C₁₀)-alkenylcarbonyloxyl, (C₂-C₁₀)-alkynylcarbonyloxy, (C₁-C₁₀)-alkylthio, (C₂-C₁₀)-alkenylthio, (C₃-C₁₀)-alkynylthio, (C₁-C₁₀)-alkylsulfinyl, (C₂-C₁₀)-alkenylsulfinyl, (C₃-C₁₀)-alkynylsulfinyl, (C₁-C₁₀)-alkylsulfonyl, (C₃-C₁₀)-alkenylsulfonyl, (C₃-C₁₀)-alkynylsulfonyl, where at least one hydrogen atom is replaced by a halogen atom as defined above. In one embodiment, all hydrogen atoms are replaced by halogen. Examples of halogenated structures are, for example, chloromethyl, trichloromethyl, fluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, trifluoromethyl, 2,2-difluoroethyl, difluoromethyl, difluoromethoxy, trifluoromethoxy, difluoromethylthio, trifluoromethylthio.

Cyclic Groups

3- to 14-membered cyclic group, unless defined differently elsewhere: (C₃-C₁₄)-carbocyclic group, 3- to 10-membered heterocyclic group, halogenated (C₃-C₁₄)-carbocyclic group, halogenated 3- to 10-membered heterocyclic group.

(C₃-C₁₄)-Carbocyclic group, unless defined differently elsewhere: (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkenyl, (C₆-C₁₄)-aryl, halogenated (C₃-C₁₄)-cycloalkyl, halogenated (C₃-C₁₄)-cycloalkenyl, halogenated (C₆-C₁₄)-aryl.

(C₃-C₁₄)-Cycloalkyl, unless defined differently elsewhere: mono-, bi- or tricyclic saturated hydrocarbon groups preferably having (C₃-C₁₄)—, (C₃-C₈)- or (C₃-C₆)-ring atoms. Cycloalkyl may also be a spirocyclic group. Examples: cyclopropyl, -butyl, -pentyl, -hexyl, -heptyl, bicyclo[2.2.1]heptyl or adamantyl. “Cycloalkyl” preferably represents monocyclic groups of 3, 4, 5, 6 or 7 ring atoms.

Analogously, (C₃-C₁₄)-cycloalkenyl, unless defined differently elsewhere, is: a mono-, bi- or tricyclic, but partially unsaturated hydrocarbon group having at least one double bond, preferably having (C₃-C₈)- or (C₃-C₆)-ring atoms. Examples: cyclopropenyl, cyclobutenyl, cyclopentenyl and cyclohexenyl.

(C₆-C₁₄)-Aryl, unless defined differently elsewhere: mono-, bi- or tricyclic ring system group where at least one cycle is aromatic, preferably having (C₆-C₈)- or (C₆)-ring atoms. Preferably, aryl is an aromatic C₆-monocyclic ring system group; a bicyclic (C₈-C₁₄)-ring system group; or a tricyclic (C₁₀-C₁₄)-ring system group. Examples: phenyl, naphthyl, anthryl, phenanthryl, tetrahydronaphthyl, indenyl, indanyl, fluorenyl.

Halogenated (C₃-C₁₄)-carbocyclic group, halogenated (C₃-C₁₄)-cycloalkyl, halogenated (C₃-C₁₄)-cycloalkenyl, halogenated (C₆-C₁₄)-aryl are in each case, unless defined differently, defined analogously to (C₃-C₁₄)-carbocyclic group, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkenyl, (C₆-C₁₄)-aryl, where at least one hydrogen atom is replaced by a halogen atom as mentioned above. In one embodiment, all hydrogen atoms are replaced by halogen. Examples of halogenated structures are 3-chlorophenyl, 2-bromocyclopentyl.

Heteroatom: for example N, O, S, P, B, Si.

3- to 10-membered heterocyclic group, unless defined differently elsewhere: 3- to 9-membered heterocyclyl group or 5- to 10-membered heteroaryl group, halogenated 3- to 9-membered heterocyclyl group or halogenated 5- to 10-membered heteroaryl group.

3- to 9-membered heterocyclyl, unless defined differently elsewhere: 3- to 9-membered saturated or partially unsaturated mono-, bi- or tricyclic ring system group of carbon atoms and at least one heteroatom preferably selected from the group consisting of N, O and S. The ring system is preferably a 3- to 6-membered ring system. Preferably, the ring system contains 1, 2, 3 or 4 heteroatoms, particularly preferably 1 or 2 heteroatoms. Preference is also given to a monocyclic ring system. In a further preferred embodiment, a monocyclic ring system is a partially unsaturated monocyclic ring system having a double bond. Heterocyclyl may be a spirocyclic system. Examples: piperazinyl, dihydropyridyl, morpholinyl, etc. This definition also applies to heterocyclyl as component of a composite substituent such as, for example, 3- to 9-membered heterocyclyl-(C₁-C₁₀)-alkyl, unless defined differently elsewhere.

5- to 10-membered heteroaryl, unless defined differently elsewhere: mono-, bi- or tricyclic 5- to 10-membered heterocyclic group of carbon atoms and at least one heteroatom, preferably selected from the group consisting of N, O and S, where at least one cycle is aromatic. The ring system is preferably a 5- to 6-membered ring system. In one embodiment, heteroaryl is an aromatic monocyclic ring system of 5 or 6 ring atoms. Preferably, heteroaryl is an aromatic monocyclic ring system containing 1 to 4 heteroatoms from the group consisting of O, N and S. Furthermore, heteroaryl may be a bicyclic ring system consisting of 8 to 14 ring atoms or a tricyclic ring system consisting of 13 or 14 ring atoms. Examples: furyl, thienyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, indolyl, benzimidazolyl, indazolyl, benzofuranyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl. This definition also applies to heteroaryl as component of a composite substituent such as, for example, 5- to 10-membered heteroaryl-(C₅-C₁₀)-alkyl, unless defined differently elsewhere. 5- and 6-membered heteroaryl groups are described in more detail below:

5-membered heteroaryl, unless defined differently elsewhere: heteroaryl group containing one to three or one to four nitrogen, oxygen and/or sulfur atom(s) as ring atoms. Examples: furanyl, thienyl, oxazolyl, thiazolyl. In one embodiment, a 5-membered heteroaryl group contains, in addition to carbon atoms, one to four nitrogen atoms or one to three nitrogen atoms as ring members. Examples: pyrrolyl, pyrazolyl, triazolyl, imidazolyl. In a further embodiment, a 5-membered heteroaryl contains one to three nitrogen atoms or one nitrogen atom and one oxygen or sulfur atom. Examples: thiazolyl, oxazolyl, oxadiazolyl.

6-membered heteroaryl, unless defined differently elsewhere: heteroaryl group containing one to three or one to four nitrogen atom(s) as ring atoms. In one embodiment, a 6-membered heteroaryl group contains one to three nitrogen atoms. Examples: pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl.

Halogenated 3- to 9-membered heterocyclyl group or halogenated 5- to 10-membered heteroaryl group, in each case unless defined differently, are defined analogously to 3- to 9-membered heterocyclyl group or 5- to 10-membered heteroaryl group, where at least one hydrogen atom is replaced by a halogen atom as mentioned above. In one embodiment, all hydrogen atoms are replaced by halogen. Example of halogenated heterocyclic structures: 3-chlorotetrahydrothiopyran-2-yl, 4-chloropyridin-2-yl.

Not included are combinations which are against natural laws and which the person skilled in the art would therefore exclude based on his/her expert knowledge. Ring structures having three or more adjacent oxygen atoms, for example, are excluded.

EMBODIMENTS OF THE COMPOUNDS ACCORDING TO THE INVENTION

It is obvious to the person skilled in the art that all embodiments can be present on their own or in combination.

The compounds of the formula (I) may, where appropriate, depending on the nature of the substituents, be in the form of salts, tautomers, geometric and/or optically active isomers or corresponding isomer mixtures in different compositions.

If appropriate, the compounds according to the invention may be present in various polymorphic forms or as a mixture of different polymorphic forms. Both the pure polymorphs and the polymorph mixtures are provided by the invention and can be used according to the invention.

Embodiments of the compounds of the formula (I) are described in more detail below:

-   X particularly preferably represents mono- or poly-M¹-substituted     phenyl, 2-thienyl, 3-thienyl, 2-furanyl or 3-furanyl; -   X particularly preferably represents mono- or tri-M¹-substituted     phenyl or 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl; -   X particularly preferably represents mono-M¹-substituted phenyl; -   X particularly preferably represents mono-M¹-substituted thienyl; -   X particularly preferably represents mono-M¹-substituted furanyl; -   X particularly preferably represents di-M¹-substituted phenyl; -   X particularly preferably represents di-M¹-substituted thienyl; -   X particularly preferably represents di-M¹-substituted furanyl; -   Q represents mono- or poly-M¹-substituted pyridyl, thienyl, furanyl     or isothiazolyl; -   Q preferably represents the structural elements below, where n for     each Q is in each case as defined below:

-   Q preferably represents the structural elements below, where n for     each Q is in each case as defined below:

-   Q particularly preferably represents mono- or poly-M¹-substituted     2-thienyl, 3-thienyl, 2-furanyl, 5-isothiazolyl, phenyl, 3-pyridyl     or 2-pyridyl; -   Q particularly preferably represents mono- or di-M¹-substituted     2-thienyl, 3-thienyl, 2-furanyl, 5-isothiazolyl, phenyl, 3-pyridyl     or 2-pyridyl; -   Q very particularly preferably represents 2-thienyl,     3-fluoro-2-thienyl, 3-chloro-2-thienyl, 3,4-dichloro-2-thienyl,     3,4,5-trichloro-2-thienyl, 3-bromo-2-thienyl, 3-iodo-2-thienyl,     3-cyano-2-thienyl, 3-methyl-2-thienyl,     3-(trifluoromethyl)-2-thienyl, 3-methoxy-2-thienyl,     3-ethoxy-2-thienyl, 3-thienyl, 2-fluoro-3-thienyl,     2-chloro-3-thienyl, 2-bromo-3-thienyl, 2-iodo-3-thienyl,     2-cyano-3-thienyl, 2-methyl-3-thienyl,     2-(trifluoromethyl)-3-thienyl, 2-methoxy-3-thienyl,     2-ethoxy-3-thienyl, 2-furanyl, 3-fluoro-2-furanyl,     3-chloro-2-furanyl, 3-bromo-2-furanyl, 3-iodo-2-furanyl,     3-cyano-2-furanyl, 3-methyl-2-furanyl,     3-(trifluoromethyl)-2-furanyl, 3-methoxy-2-furanyl,     3-ethoxy-2-furanyl, 3-furanyl, 2-chloro-3-furanyl,     2-bromo-3-furanyl, 2-iodo-3-furanyl, 2-cyano-3-furanyl,     2-methyl-3-furanyl, 2-(trifluoromethyl)-3-furanyl,     2-methoxy-3-furanyl, 2-ethoxy-3-furanyl, 4-chloro-5-isothiazolyl,     3,4-dichloro-5-isothiazolyl, 2-fluorophenyl, 2,6-difluorophenyl,     2-chlorophenyl, 2,6-dichlorophenyl, 2-bromophenyl, 2-iodophenyl,     2-(difluoromethyl)phenyl, 2-(trifluoromethyl)phenyl,     2-chloro-3-pyridyl, 3-chloro-2-pyridyl or     2-(trifluoromethyl)-3-pyridyl; -   Q in particular very particularly preferably represents     3-chloro-2-thienyl, 3,4,5-trichloro-2-thienyl, 3-bromo-2-thienyl,     3-iodo-2-thienyl, 3-cyano-2-thienyl, 3-methyl-2-thienyl,     3-(trifluoromethyl)-2-thienyl, 3-methoxy-2-thienyl,     3-ethoxy-2-thienyl, 2-chloro-3-thienyl, 2-bromo-3-thienyl,     2-iodo-3-thienyl, 2-methyl-3-thienyl, 3-bromo-2-furanyl,     3-methyl-2-furanyl, 2-chloro-3-furanyl, 2-bromo-3-furanyl,     2-iodo-3-furanyl, 2-methyl-3-furanyl, 3,4-dichloro-5-isothiazolyl,     2-fluorophenyl, 2,6-difluorophenyl, 2-chlorophenyl,     2,6-dichlorophenyl, 2-bromophenyl, 2-iodophenyl,     2-(difluoromethyl)phenyl, 2-(trifluoromethyl)phenyl,     2-chloro-3-pyridyl, 3-chloro-2-pyridyl or     2-(trifluoromethyl)-3-pyridyl; -   Q particularly preferably represents mono- or poly-M¹-substituted     2-thienyl, 3-thienyl, 2-furanyl, 5-isothiazolyl, 3-pyridyl or     2-pyridyl; -   Q particularly preferably represents mono- or di-M¹-substituted     2-thienyl, 3-thienyl, 2-furanyl, 5-isothiazolyl, 3-pyridyl or     2-pyridyl; -   Q very particularly preferably represents 2-thienyl,     3-fluoro-2-thienyl, 3-chloro-2-thienyl, 3,4-dichloro-2-thienyl,     3,4,5-trichloro-2-thienyl, 3-bromo-2-thienyl, 3-iodo-2-thienyl,     3-cyano-2-thienyl, 3-methyl-2-thienyl,     3-(trifluoromethyl)-2-thienyl, 3-methoxy-2-thienyl,     3-ethoxy-2-thienyl, 3-thienyl, 2-fluoro-3-thienyl,     2-chloro-3-thienyl, 2-bromo-3-thienyl, 2-iodo-3-thienyl,     2-cyano-3-thienyl, 2-methyl-3-thienyl,     2-(trifluoromethyl)-3-thienyl, 2-methoxy-3-thienyl,     2-ethoxy-3-thienyl, 2-furanyl, 3-fluoro-2-furanyl,     3-chloro-2-furanyl, 3-bromo-2-furanyl, 3-iodo-2-furanyl,     3-cyano-2-furanyl, 3-methyl-2-furanyl,     3-(trifluoromethyl)-2-furanyl, 3-methoxy-2-furanyl,     3-ethoxy-2-furanyl, 3-furanyl, 2-chloro-3-furanyl,     2-bromo-3-furanyl, 2-iodo-3-furanyl, 2-cyano-3-furanyl,     2-methyl-3-furanyl, 2-(trifluoromethyl)-3-furanyl,     2-methoxy-3-furanyl, 2-ethoxy-3-furanyl, 4-chloro-5-isothiazolyl,     3,4-dichloro-5-isothiazolyl, 2-chloro-3-pyridyl, 3-chloro-2-pyridyl     or 2-(trifluoromethyl)-3-pyridyl. -   Q in particular very particularly preferably represents     3-chloro-2-thienyl, 3,4,5-trichloro-2-thienyl, 3-bromo-2-thienyl,     3-iodo-2-thienyl, 3-cyano-2-thienyl, 3-methyl-2-thienyl,     3-(trifluoromethyl)-2-thienyl, 3-methoxy-2-thienyl,     3-ethoxy-2-thienyl, 2-chloro-3-thienyl, 2-bromo-3-thienyl,     2-iodo-3-thienyl, 2-methyl-3-thienyl, 3-bromo-2-furanyl,     3-methyl-2-furanyl, 2-chloro-3-furanyl, 2-bromo-3-furanyl,     2-iodo-3-furanyl, 2-methyl-3-furanyl, 3,4-dichloro-5-isothiazolyl,     2-chloro-3-pyridyl, 3-chloro-2-pyridyl or     2-(trifluoromethyl)-3-pyridyl; -   Y preferably represents hydrogen or represents optionally mono- or     poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl,     (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl,     (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₂-C₁₀)-alkenyloxy,     (C₃-C₁₀)-alkynyloxy, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or     represents an optionally mono- or poly-M²-substituted 3- to     14-membered cyclic group; -   Y preferably represents hydrogen or represents optionally mono- or     poly-M²-substituted (C₁-C₄)-alkyl, (C₂-C₄)-alkenyl, (C₃-C₄)-alkynyl,     (C₁-C₄)-haloalkyl, (C₂-C₄)-haloalkenyl, (C₃-C₄)-haloalkynyl,     (C₁-C₄)-alkoxy, (C₂-C₄)-alkenyloxy, (C₃-C₄)-alkynyloxy,     (C₃-C₆)-cycloalkyl-(C₁-C₄)-alkyl or represents an optionally mono-     or poly-M²-substituted C₃- to C₆-membered carbocyclic group; -   Y particularly preferably represents hydrogen, methyl, ethyl,     n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,     cyanomethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, allyl,     butenyl, propargyl, butynyl, 3,3-dichloroprop-2-enyl, methoxy,     ethoxy, cyclopropylmethyl, cyclopropyl, cyclobutyl, cyclopentyl or     cyclohexyl; -   Y very particularly preferably represents hydrogen, methyl, ethyl,     n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,     methoxy, ethoxy, cyclopropylmethyl, cyclopropyl, cyclobutyl; -   Y very particularly preferably represents hydrogen, cyclopropyl; -   W preferably represents oxygen; -   W preferably represents sulfur; -   L¹ preferably represents —C(R¹¹, R¹²)—, oxygen or —N(R¹)—; -   L¹ very particularly preferably represents —C(R¹¹, R¹²)— or —N(R¹)—; -   L¹ particularly preferably represents —C(R¹¹, R¹²)—; -   L¹ particularly preferably represents oxygen; -   L¹ particularly preferably represents —N(R¹)—; -   L³ preferably represents a direct bond; -   L³ preferably represents —C(R³¹, R³²)—; -   M¹ preferably represents hydrogen, halogen, cyano, nitro, OH,     (C₁-C₆)-alkyl, (C₁-C₆)-haloalkyl, (C₁-C₆)-alkoxy,     (C₁-C₆)-haloalkoxy, (C₁-C₆)-alkylthio, (C₁-C₆)-haloalkylthio,     (C₁-C₆)-alkylsulfonyl, (C₁-C₆)-haloalkylsulfonyl,     (C₁-C₆)-alkylsulfanyl, (C₁-C₆)-haloalkylsulfanyl,     (C₃-C₁₄)-cycloalkyl-O—, (C₃-C₁₄)-cycloalkenyl-O—, (C₆-C₁₄)-aryl-O—,     halogenated (C₃-C₁₄)-cycloalkyl-O—, halogenated     (C₃-C₁₄)-cycloalkenyl-O—, halogenated (C₆-C₁₄)-aryl-O—; -   M¹ preferably represents hydrogen, halogen, cyano, nitro, OH,     (C₁-C₄)-alkyl, (C₁-C₄)-haloalkyl, (C₁-C₄)-alkoxy,     (C₁-C₄)-haloalkoxy, (C₁-C₄)-alkylthio, (C₁-C₄)-haloalkylthio,     (C₁-C₄)-alkylsulfonyl, (C₁-C₄)-haloalkylsulfonyl,     (C₁-C₄)-alkylsulfanyl, (C₁-C₆)-haloalkylsulfanyl,     (C₃-C₁₄)-cycloalkyl-O—, (C₃-C₁₄)-cycloalkenyl-O—, (C₆-C₁₄)-aryl-O—,     halogenated (C₃-C₁₄)-cycloalkyl-O—, halogenated     (C₃-C₁₄)-cycloalkenyl-O—, halogenated (C₆-C₁₄)-aryl-O—; -   M¹ very particularly preferably represents hydrogen, halogen, cyano,     nitro, OH, (C₁-C₄)-alkyl, (C₁-C₄)-haloalkyl, (C₁-C₄)-alkoxy,     (C₁-C₄)-haloalkoxy, (C₁-C₄)-alkylthio, (C₁-C₄)-haloalkylthio,     (C₁-C₄)-alkylsulfonyl, (C₁-C₄)-haloalkylsulfonyl,     (C₁-C₄)-alkylsulfanyl, (C₁-C₆)-haloalkylsulfanyl, (C₆-C₁₄)-aryl-O—,     halogenated (C₆-C₁₄)-aryl)-O—; -   M¹ very particularly preferably represents hydrogen, fluorine,     bromine, chlorine, iodine, cyano, nitro, OH, methyl, ethyl,     isopropyl, tert-butyl, trifluoromethyl, difluoromethyl, methoxy,     ethoxy, isopropoxy, trifluoromethoxy, difluoromethoxy, methylthio,     trifluoromethylthio, difluoromethylthio, 2,2,2-trifluoroethylthio,     methylsulfonyl, ethylsulfonyl, trifluoromethylsulfonyl,     2,2,2-trifluoroethylsulfonyl, methylsulfanyl, ethylsulfanyl,     trifluoromethylsulfanyl, 2,2,2-trifluoroethylsulfanyl or phenoxy; -   M¹ in particular very particularly preferably represents hydrogen,     fluorine, bromine, chlorine, iodine, cyano, methyl, trifluoromethyl,     difluoromethyl, methoxy, ethoxy, isopropoxy or phenoxy; -   R¹ preferably represents hydrogen or optionally mono- or     poly-M²-substituted (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl,     (C₁-C₆)-haloalkyl, (C₂-C₆)-haloalkenyl, (C₂-C₆)-haloalkynyl,     (C₃-C₆)—-cycloalkyl-(C₁-C₆)-alkyl or represents an optionally mono-     or poly-M²-substituted (C₃-C₁₄)-carbocyclic group; -   R¹ preferably represents hydrogen or optionally mono- or     poly-M²-substituted (C₁-C₄)-alkyl, (C₂-C₄)-alkenyl, (C₂-C₄)-alkynyl,     (C₁-C₄)-haloalkyl, (C₂-C₄)-haloalkenyl, (C₂-C₄)-haloalkynyl,     (C₃-C₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represents optionally mono- or     poly-M²-substituted (C₃-C₈)-cycloalkyl or halogenated     (C₃-C₈)-cycloalkyl; -   R¹ particularly preferably represents hydrogen or methyl, ethyl,     n-propyl, isopropyl, allyl, propargyl, cyclopropylmethyl or     cyclopropyl; -   R¹ very particularly preferably represents hydrogen or     (C₁-C₄)-alkyl; -   R¹ particularly preferably represents hydrogen or methyl, ethyl,     n-propyl, isopropyl; -   R¹¹, R¹² preferably each independently of one another represent     hydrogen, fluorine or optionally mono- or poly-M²-substituted     (C₁-C₁₀)-alkyl, (C₁-C₁₀)-haloalkyl, (C₁-C₁₀)-alkoxy,     (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represent an optionally mono-     or poly-M²-substituted (C₃-C₁₄)-carbocyclic group; -   R¹¹, R¹² particularly preferably each independently of one another     represent hydrogen, fluorine or optionally mono- or     poly-M²-substituted (C₁-C₆)-alkyl, (C₁-C₆)-haloalkyl,     (C₁-C₆)-alkoxy, (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl     or halogenated (C₃-C₈)-cycloalkyl; -   R¹¹, R¹² very particularly preferably each independently of one     another represent hydrogen, fluorine or (C₁-C₆)-alkyl,     (C₁-C₆)-haloalkyl, (C₁-C₆)-alkoxy, (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl,     (C₃-C₆)-cycloalkyl; -   R¹¹, R¹² very particularly preferably each independently of one     another represent hydrogen, fluorine, methyl, ethyl, n-propyl,     isopropyl, trifluoromethyl, allyl, propargyl, methoxy, ethoxy,     allyloxy, propargyloxy, cyclopropylmethyl, cyclopropyl; -   R¹¹, R¹² very particularly preferably each independently of one     another represent hydrogen, fluorine, methyl, ethyl, n-propyl,     isopropyl, allyl, propargyl, methoxy, ethoxy, allyloxy,     propargyloxy, cyclopropylmethyl, cyclopropyl; -   R¹¹, R¹² very particularly preferably each independently of one     another represent hydrogen, fluorine, methyl, ethyl, n-propyl,     isopropyl, allyl, propargyl, methoxy, ethoxy, allyloxy,     propargyloxy, cyclopropylmethyl, cyclopropyl; R¹¹, R¹² very     particularly preferably each independently of one another represent     hydrogen, fluorine, methyl, ethyl, n-propyl, isopropyl, methoxy,     ethoxy or -   R¹¹, R¹² very particularly preferably represent C(R¹¹, R¹²) as     spiro-C(CH₂—CH₂); -   R¹¹, R¹² in particular very particularly preferably each     independently of one another represent hydrogen, (C₁-C₆)-alkoxy or     (C₁-C₆)-alkyl; -   R¹¹, R¹² in particular very particularly preferably independently of     one another represent hydrogen, halogen, (C₁-C₆)-haloalkyl,     (C₁-C₆)-alkoxy or (C₁-C₆)-alkyl; R¹¹, R¹² especially very     particularly preferably independently of one another represent     hydrogen, methoxy, methyl, ethyl; -   R¹¹, R¹² in particular very particularly preferably independently of     one another represent hydrogen, methoxy, methyl, ethyl,     trifluoromethyl, fluorine; -   R²¹, R²² preferably each independently of one another represent     hydrogen, fluorine or optionally mono- or poly-M²-substituted     (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₁-C₆)-haloalkyl,     (C₂-C₆)-haloalkenyl, (C₂-C₆)-haloalkynyl, (C₁-C₆)-alkoxy,     (C₁-C₆)-haloalkoxy, (C₂-C₆)-alkenyloxy, (C₃-C₆)-alkynyloxy,     (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl or represent an optionally mono- or     poly-M²-substituted (C₃-C₁₄)-carbocyclic group; -   R²¹, R²² preferably each independently of one another represent     hydrogen, fluorine or optionally mono- or poly-M²-substituted     (C₁-C₄)-alkyl, (C₂-C₄)-alkenyl, (C₂-C₄)-alkynyl, (C₁-C₄)-haloalkyl,     (C₂-C₄)-haloalkenyl, (C₂-C₄)-haloalkynyl, (C₁-C₆)-alkoxy,     (C₁-C₄)-haloalkoxy, (C₂-C₄)-alkenyloxy, (C₃-C₄)-alkynyloxy,     (C₃-C₄)-cycloalkyl-(C₁-C₄)-alkyl, (C₃-C₈)-cycloalkyl or halogenated     (C₃-C₈)-cycloalkyl; -   R²¹, R²² particularly preferably each independently of one another     represent hydrogen, fluorine or optionally mono- or     poly-M²-substituted (C₁-C₄)-alkyl, (C₂-C₄)-alkenyl, (C₂-C₄)-alkynyl,     (C₁-C₄)-haloalkyl, (C₁-C₆)-alkoxy, (C₂-C₄)-alkenyloxy,     (C₃-C₄)-alkynyloxy, (C₃-C₄)-cycloalkyl-(C₁-C₄)-alkyl,     (C₃-C₆)-cycloalkyl; -   R²¹, R²² preferably each independently of one another represent     hydrogen, fluorine, methyl, ethyl, n-propyl, isopropyl, allyl,     propargyl, methoxy, ethoxy, allyloxy, propargyloxy,     cyclopropylmethyl, cyclopropyl; -   R²¹, R²² very particularly preferably each independently of one     another represent hydrogen, fluorine or (C₁-C₄)-alkyl,     (C₁-C₄)-haloalkyl; -   R²¹, R²² in particular very particularly preferably each     independently of one another represent hydrogen, fluorine or methyl,     ethyl; -   R²¹, R²² very particularly preferably represent C(R²¹, R²²) as     spiro-C(CH₂—CH₂); -   R³¹, R³² preferably each independently of one another represent     hydrogen or optionally mono- or poly-M²-substituted (C₁-C₆)-alkyl,     (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₁-C₆)-haloalkyl,     (C₂-C₆)-haloalkenyl, (C₂-C₆)-haloalkynyl, (C₁-C₆)-alkoxy,     (C₁-C₆)-haloalkoxy, (C₂-C₆)-alkenyloxy, (C₃-C₆)-alkynyloxy,     (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl or represent an optionally mono- or     poly-M²-substituted (C₃-C₁₄)-carbocyclic group; -   R³¹, R³² preferably each independently of one another represent     hydrogen or optionally mono- or poly-M²-substituted (C₁-C₄)-alkyl,     (C₂-C₄)-alkenyl, (C₂-C₄)-alkynyl, (C₁-C₄)-haloalkyl,     (C₂-C₄)-haloalkenyl, (C₂-C₄)-haloalkynyl, (C₁-C₆)-alkoxy,     (C₁-C₄)-haloalkoxy, (C₂-C₄)-alkenyloxy, (C₃-C₄)-alkynyloxy,     (C₃-C₄)-cycloalkyl-(C₁-C₄)-alkyl or represent an optionally mono- or     poly-M²-substituted (C₃-C₈)-cycloalkyl or halogenated     (C₃-C₈)-cycloalkyl; -   R³¹, R³² particularly preferably each independently of one another     represent hydrogen or optionally mono- or poly-M²-substituted     (C₁-C₄)-alkyl, (C₁-C₄)-haloalkyl, (C₂-C₄)-haloalkenyl,     (C₂-C₄)-alkenyl, (C₂-C₄)-alkynyl, (C₁-C₆)-alkoxy,     (C₂-C₄)-alkenyloxy, (C₃-C₄)-alkynyloxy,     (C₃-C₄)-cycloalkyl-(C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl; -   R³¹, R³² particularly preferably each independently of one another     represent hydrogen, methyl, ethyl, n-propyl, isopropyl, tert-butyl,     allyl, propargyl, methoxy, ethoxy, allyloxy, propargyloxy,     cyclopropylmethyl, cyclopropyl; -   R³¹, R³² very particularly preferably each independently of one     another represent hydrogen or (C₁-C₄)-alkyl; -   R³¹, R³² in particular very particularly preferably each     independently of one another represent hydrogen, methyl, ethyl,     n-propyl, isopropyl or tert-butyl; -   R³¹, R³² very particularly preferably represent C(R³¹, R³²) as     spiro-C(CH₂—CH₂); -   M² preferably each independently of one another represent halogen,     formyl, cyano, nitro, (C₁-C₆)-alkyl, (C₁-C₆)-haloalkyl,     (C₂-C₆)-alkenyl, (C₂-C₆)-haloalkenyl, (C₂-C₆)-alkynyl,     (C₂-C₆)-haloalkynyl, (C₁-C₆)-alkoxy, (C₁-C₆)-haloalkoxy,     (C_(uG)-C_(oG))-alkenyloxy, (C₂-C₆)-haloalkenyloxy,     (C₃-C₆)-alkynyloxy, (C₃-C₆)-haloalkynyloxy, (C₁-C₆)-alkylthio,     (C₁-C₆)-haloalkylthio, (C₂-C₆)-alkenylthio, (C₂-C₆)-haloalkenylthio,     (C₃-C₆)-alkynylthio, (C₃-C₆)-haloalkynylthio, (C₁-C₆)-alkylsulfonyl,     (C₁-C₆)-haloalkylsulfonyl, (C₂-C₆)-alkenylsulfonyl,     (C₂-C₆)-haloalkenylsulfonyl, (C₃-C₆)-alkynylsulfonyl,     (C₃-C₆)-haloalkynylsulfonyl, (C₁-C₆)-alkylsulfanyl,     (C₁-C₆)-haloalkylsulfanyl, (C₂-C₆)-alkenylsulfanyl,     (C₂-C₆)-haloalkenylsulfanyl, (C₃-C₆)-alkynylsulfanyl,     (C₃-C₆)-haloalkynylsulfanyl, formyl, (C₁-C₆)-alkylcarbonyl,     (C₁-C₆)-haloalkylcarbonyl, (C₂-C₆)-alkenylcarbonyl,     (C₂-C₆)-haloalkenylcarbonyl, (C₂-C₆)-alkynylcarbonyl,     (C₂-C₆)-haloalkynylcarbonyl, (C₁-C₆)-alkoxycarbonyl,     (C₁-C₆)-haloalkoxycarbonyl, (C₂-C₆)-alkenyloxycarbonyl,     (C₂-C₆)-haloalkenyloxycarbonyl, (C₃-C₆)-alkynyloxycarbonyl,     (C₃-C₆)-haloalkynyloxycarbonyl, (C₁-C₆)-alkylcarbonyloxy,     (C₁-C₆)-haloalkylcarbonyloxy, (C₂-C₆)-alkenylcarbonyloxy,     (C₂-C₆)-haloalkenylcarbonyloxy, (C₂-C₆)-alkynylcarbonyloxy,     (C₂-C₆)-haloalkynylcarbonyloxy or (C₃-C₁₄)-cycloalkyl. -   M² particularly preferably each independently of one another     represent halogen, formyl, cyano, nitro, (C₁-C₄)-alkyl,     (C₁-C₄)-haloalkyl, (C₂-C₄)-alkenyl, (C₂-C₄)-haloalkenyl,     (C₂-C₄)-alkynyl, (C₂-C₄)-haloalkynyl, (C₁-C₄)-alkoxy,     (C₁-C₄)-haloalkoxy, (C₂-C₄)-alkenyloxy, (C₂-C₄)-haloalkenyloxy,     (C₃-C₄)-alkynyloxy, (C₃-C₄)-haloalkynyloxy, (C₁-C₄)-alkylthio,     (C₁-C₄)-haloalkylthio, (C₂-C₄)-alkenylthio, (C₂-C₄)-haloalkenylthio,     (C₃-C₄)-alkynylthio, (C₃-C₄)-haloalkynylthio, (C₁-C₄)-alkylsulfonyl,     (C₁-C₄)-haloalkylsulfonyl, (C₂-C₄)-alkenylsulfonyl,     (C₂-C₄)-haloalkenylsulfonyl, (C₃-C₄)-alkynylsulfonyl,     (C₃-C₄)-haloalkynylsulfonyl, (C₁-C₄)-alkylsulfanyl,     (C₁-C₄)-haloalkylsulfanyl, (C₂-C₄)-alkenylsulfanyl,     (C₂-C₄)-haloalkenylsulfanyl, (C₃-C₄)-alkynylsulfanyl,     (C₃-C₄)-haloalkynylsulfanyl, (C₁-C₄)-alkylcarbonyl,     (C₁-C₄)-haloalkylcarbonyl, (C₂-C₄)-alkenylcarbonyl,     (C₂-C₄)-haloalkenylcarbonyl, (C₂-C₄)-alkynylcarbonyl,     (C₂-C₄)-haloalkynylcarbonyl, (C₁-C₄)-alkoxycarbonyl,     (C₁-C₄)-haloalkoxycarbonyl, (C₂-C₄)-alkenyloxycarbonyl,     (C₂-C₄)-haloalkenyloxycarbonyl, (C₃-C₄)-alkynyloxycarbonyl,     (C₃-C₄)-haloalkynyloxycarbonyl, (C₁-C₄)-alkylcarbonyloxy,     (C₁-C₄)-haloalkylcarbonyloxy, (C₂-C₄)-alkenylcarbonyloxy,     (C₂-C₄)-haloalkenylcarbonyloxy, (C₂-C₄)-alkynylcarbonyloxy,     (C₂-C₄)-haloalkynylcarbonyloxy or (C₃-C₆)-cycloalkyl. -   M² very particularly preferably each independently of one another     represent chlorine, fluorine, formyl, cyano, nitro, (C₁-C₄)-alkyl,     (C₁-C₄)-haloalkyl, (C₁-C₄)-alkoxy, (C₁-C₄)-haloalkoxy,     (C₁-C₄)-alkylthio, (C₁-C₄)-haloalkylthio, (C₁-C₄)-alkylsulfonyl,     (C₁-C₄)-haloalkylsulfonyl, (C₁-C₄)-alkylsulfanyl,     (C₁-C₄)-haloalkylsulfanyl, (C₁-C₄)-alkylcarbonyl,     (C₁-C₄)-haloalkylcarbonyl or (C₃-C₆)-cycloalkyl. -   M² very particularly preferably each independently of one another     represent fluorine, bromine, chlorine, iodine, cyano, nitro, methyl,     ethyl, isopropyl, tert-butyl, trifluoromethyl, difluoromethyl,     methoxy, ethoxy, isopropoxy, trifluoromethoxy, difluoromethoxy,     methylthio, trifluoromethylthio, difluoromethylthio,     2,2,2-trifluoroethylthio, methylsulfonyl, ethylsulfonyl,     trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl,     methylsulfanyl, ethylsulfanyl, trifluoromethylsulfanyl,     2,2,2-trifluoroethylsulfanyl, cyclopropyl, cyclobutyl or     cyclopentyl.

However, the general or preferred radical definitions or explanations given above can also be combined with one another as desired, i.e. including combinations between the respective ranges and preferred ranges. They apply both to the end products and, correspondingly, to precursors and intermediates.

The definitions mentioned can be combined with one another as desired. Moreover, individual definitions may not apply.

Preference, particular preference and very particular preference is given to compounds of the formula (I) which carry the substituents mentioned under preferred, particularly preferred, very particularly preferred or in particular very particularly preferred in each case.

In one embodiment, compounds of the formula (I) are compounds

in which L¹, L², L³, Q, W and Y are as defined above and

-   X represents phenyl, preferably mono- or polysubstituted by M¹     selected from the group consisting of hydrogen, halogen, cyano,     nitro, OH, (C₁-C₄)-alkyl, (C₁-C₃)-haloalkyl, (C₁-C₄)-alkoxy,     (C₁-C₃)-haloalkoxy, (C₁-C₄)-alkylthio, (C₁-C₃)-haloalkylthio,     (C₁-C₄)-alkylsulfonyl, (C₁-C₃)-haloalkylsulfonyl,     (C₁-C₄)-alkylsulfanyl, (C₁-C₃)-haloalkylsulfanyl and phenoxy; -   X represents phenyl, particularly preferably mono- or     polysubstituted by M¹ selected from the group consisting of     hydrogen, fluorine, bromine, chlorine, iodine, cyano, nitro, OH,     methyl, ethyl, isopropyl, tert-butyl, trifluoromethyl,     difluoromethyl, methoxy, ethoxy, isopropoxy, trifluoromethoxy,     difluoromethoxy, methylthio, trifluoromethylthio,     difluoromethylthio, 2,2,2-trifluoroethylthio, methylsulfonyl,     ethylsulfonyl, trifluoromethylsulfonyl,     2,2,2-trifluoroethylsulfonyl, methylsulfanyl, ethylsulfanyl,     trifluoromethylsulfanyl, 2,2,2-trifluoroethylsulfanyl and phenoxy; -   X represents 2-thienyl, preferably mono- or polysubstituted by M¹     selected from the group consisting of hydrogen, halogen, cyano,     nitro, OH, optionally substituted (C₁-C₄)-alkyl, (C₁-C₃)-haloalkyl,     (C₁-C₄)-alkoxy and (C₁-C₃)-haloalkoxy; -   X represents 2-thienyl, particularly preferably mono- or     polysubstituted by M¹ selected from the group consisting of     hydrogen, fluorine, chlorine, bromine, iodine, methyl and     trifluoromethyl; -   X represents 3-thienyl, preferably mono- or polysubstituted by M¹     selected from the group consisting of hydrogen, halogen, cyano,     nitro, OH, optionally substituted (C₁-C₄)-alkyl, (C₁-C₃)-haloalkyl,     (C₁-C₄)-alkoxy and (C₁-C₃)-haloalkoxy; -   X represents 3-thienyl, particularly preferably mono- or     polysubstituted by M¹ selected from the group consisting of     hydrogen, fluorine, chlorine, bromine, iodine, methyl and     trifluoromethyl; -   X represents 2-furanyl, preferably mono- or polysubstituted by M¹     selected from the group consisting of hydrogen, halogen, cyano,     nitro, OH, optionally substituted (C₁-C₄)-alkyl, (C₁-C₃)-haloalkyl,     (C₁-C₄)-alkoxy and (C₁-C₃)-haloalkoxy; -   X represents 2-furanyl, particularly preferably mono- or     polysubstituted by M¹ selected from the group consisting of     hydrogen, fluorine, chlorine, bromine, iodine, methyl and     trifluoromethyl. -   X represents 3-furanyl, preferably mono- or polysubstituted by M¹     selected from the group consisting of hydrogen, halogen, cyano,     nitro, OH, optionally substituted (C₁-C₄)-alkyl, (C₁-C₃)-haloalkyl,     (C₁-C₄)-alkoxy and (C₁-C₃)-haloalkoxy; -   X represents 3-furanyl, particularly preferably mono- or     polysubstituted by M¹ selected from the group consisting of     hydrogen, fluorine, chlorine, bromine, iodine, methyl and     trifluoromethyl.

In a further embodiment, compounds of the formula (I) are compounds

in which L¹, L², L³, W, X and Y are as defined above and

-   Q preferably represents the following structural elements which may     be mono- or polysubstituted by M¹ selected from the group consisting     of hydrogen, halogen, cyano, optionally substituted (C₁-C₄)-alkyl,     (C₁-C₃)-haloalkyl or (C₁-C₄)-alkoxy:

-   Q particularly preferably represents 2-thienyl, 3-fluoro-2-thienyl,     3-chloro-2-thienyl, 3,4-dichloro-2-thienyl,     3,4,5-trichloro-2-thienyl, 3-bromo-2-thienyl, 3-iodo-2-thienyl,     3-cyano-2-thienyl, 3-methyl-2-thienyl,     3-(trifluoromethyl)-2-thienyl, 3-methoxy-2-thienyl,     3-ethoxy-2-thienyl, 3-thienyl, 2-fluoro-3-thienyl,     2-chloro-3-thienyl, 2-bromo-3-thienyl, 2-iodo-3-thienyl,     2-cyano-3-thienyl, 2-methyl-3-thienyl,     2-(trifluoromethyl)-3-thienyl, 2-methoxy-3-thienyl,     2-ethoxy-3-thienyl, 2-furanyl, 3-fluoro-2-furanyl,     3-chloro-2-furanyl, 3-bromo-2-furanyl, 3-iodo-2-furanyl,     3-cyano-2-furanyl, 3-methyl-2-furanyl,     3-(trifluoromethyl)-2-furanyl, 3-methoxy-2-furanyl,     3-ethoxy-2-furanyl, 3-furanyl, 2-chloro-3-furanyl,     2-bromo-3-furanyl, 2-iodo-3-furanyl, 2-cyano-3-furanyl,     2-methyl-3-furanyl, 2-(trifluoromethyl)-3-furanyl,     2-methoxy-3-furanyl, 2-ethoxy-3-furanyl, 4-chloro-5-isothiazolyl,     3,4-dichloro-5-isothiazolyl, 2-fluorophenyl, 2,6-difluorophenyl,     2-chlorophenyl, 2,6-dichlorophenyl, 2-bromophenyl, 2-iodophenyl,     2-(difluoromethyl)phenyl, 2-(trifluoromethyl)phenyl,     2-chloro-3-pyridyl, 3-chloro-2-pyridyl or     2-(trifluoromethyl)-3-pyridyl. -   Q preferably represents the following structural elements which may     be mono- or polysubstituted by M¹ selected from the group consisting     of hydrogen, halogen, cyano, optionally substituted (C₁-C₄)-alkyl,     (C₁-C₃)-haloalkyl or (C₁-C₄)-alkoxy:

-   Q particularly preferably represents 2-thienyl, 3-fluoro-2-thienyl,     3-chloro-2-thienyl, 3,4-dichloro-2-thienyl,     3,4,5-trichloro-2-thienyl, 3-bromo-2-thienyl, 3-iodo-2-thienyl,     3-cyano-2-thienyl, 3-methyl-2-thienyl,     3-(trifluoromethyl)-2-thienyl, 3-methoxy-2-thienyl,     3-ethoxy-2-thienyl, 3-thienyl, 2-fluoro-3-thienyl,     2-chloro-3-thienyl, 2-bromo-3-thienyl, 2-iodo-3-thienyl,     2-cyano-3-thienyl, 2-methyl-3-thienyl,     2-(trifluoromethyl)-3-thienyl, 2-methoxy-3-thienyl,     2-ethoxy-3-thienyl, 2-furanyl, 3-fluoro-2-furanyl,     3-chloro-2-furanyl, 3-bromo-2-furanyl, 3-iodo-2-furanyl,     3-cyano-2-furanyl, 3-methyl-2-furanyl,     3-(trifluoromethyl)-2-furanyl, 3-methoxy-2-furanyl,     3-ethoxy-2-furanyl, 3-furanyl, 2-chloro-3-furanyl,     2-bromo-3-furanyl, 2-iodo-3-furanyl, 2-cyano-3-furanyl,     2-methyl-3-furanyl, 2-(trifluoromethyl)-3-furanyl,     2-methoxy-3-furanyl, 2-ethoxy-3-furanyl, 4-chloro-5-isothiazolyl,     3,4-dichloro-5-isothiazolyl, 2-chloro-3-pyridyl, 3-chloro-2-pyridyl     or 2-(trifluoromethyl)-3-pyridyl;     and salts, N-oxides and tautomeric forms of the compounds of the     formula (I).

In a further embodiment, compounds of the formula (I) are compounds

in which L¹, L², L³, Q, W and X are as defined above and

-   Y preferably represents hydrogen or represents optionally mono- or     poly-M²-substituted (C₁-C₄)-alkyl, (C₂-C₄)-alkenyl, (C₃-C₄)-alkynyl,     (C₁-C₄)-haloalkyl, (C₂-C₄)-haloalkenyl, (C₃-C₄)-haloalkynyl,     (C₁-C₄)-alkoxy, (C₂-C₄)-alkenyloxy, (C₃-C₄)-alkynyloxy,     (C₃-C₆)-cycloalkyl-(C₁-C₄)-alkyl or represents an optionally     substituted C₃- to C₆-membered carbocyclic group; -   Y particularly preferably represents hydrogen, methyl, ethyl,     n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,     cyanomethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, allyl,     butenyl, propargyl, butynyl, 3,3-dichloroprop-2-enyl, methoxy,     ethoxy, cyclopropylmethyl, cyclopropyl, cyclobutyl, cyclopentyl or     cyclohexyl;     and salts, N-oxides and tautomeric forms of the compounds of the     formula (I).

In a further embodiment, compounds of the formula (I) are compounds

in which L¹, L², L³, Q, X and Y are as defined above and

-   W preferably represents oxygen;     and salts, N-oxides and tautomeric forms of the compounds of the     formula (I).

In a further embodiment, compounds of the formula (I) are compounds

in which L², L³, Q, W, X and Y are as defined above and

-   L¹ preferably represents C(R¹¹, R¹²), where R¹¹ and R¹² each     independently of one another represent hydrogen, fluorine or     optionally mono- or poly-M²-substituted (C₁-C₄)-alkyl,     (C₃-C₄)-alkenyl, (C₃-C₄)-alkynyl, (C₁-C₄)-haloalkyl,     (C₃-C₄)-haloalkenyl, (C₃-C₄)-haloalkynyl, (C₁-C₄)-alkoxy,     (C₃-C₄)-alkenyloxy, (C₃-C₄)-alkynyloxy,     (C₃-C₆)-cycloalkyl-(C₁-C₄)-alkyl or represents an optionally     substituted C₃- to C₆-membered carbocyclic group, or where R¹¹ and     R¹² together represent an optionally substituted spiro-linked 3- to     6-membered cyclic group; -   L¹ preferably represents oxygen or sulfur; -   L¹ preferably represents —N(R¹) where R² represents hydrogen or     optionally mono- or poly-M²-substituted (C₁-C₄)-alkyl,     (C₃-C₄)-alkenyl, (C₃-C₄)-alkynyl, (C₁-C₄)-haloalkyl,     (C₃-C₄)-haloalkenyl, (C₃-C₄)-haloalkynyl,     (C₃-C₆)-cycloalkyl-(C₁-C₄)-alkyl or represent an optionally     substituted C₃- to C₆-membered carbocyclic group; -   L¹ particularly preferably represents C(R¹¹, R¹²) where R¹¹ and R¹²     each independently of one another represent hydrogen, fluorine,     methyl, ethyl, n-propyl, isopropyl, allyl, propargyl, methoxy,     ethoxy, allyloxy, propargyloxy, cyclopropylmethyl, cyclopropyl, or     where C(R¹¹, R¹²) represents spiro-C(CH₂—CH₂); -   L¹ particularly preferably represents oxygen;     and salts, N-oxides and tautomeric forms of the compounds of the     formula (I).

In a further embodiment, compounds of the formula (I) are compounds

in which L², L³, W, X and Y are as defined above and

-   Q preferably represents a mono- or poly-M¹-substituted phenyl,     pyridyl, thienyl, furanyl or isothiazolyl; -   Q preferably represents a mono- or poly-M¹-substituted pyridyl,     thienyl, furanyl or isothiazolyl; -   Q particularly preferably represents a mono- or poly-M¹-substituted     phenyl; -   L¹ preferably represents oxygen or sulfur; -   L¹ preferably represents —N(R¹) where R¹ represents hydrogen or     optionally mono- or poly-M²-substituted (C₁-C₄)-alkyl,     (C₃-C₄)-alkenyl, (C₃-C₄)-alkynyl, (C₁-C₄)-haloalkyl,     (C₃-C₄)-haloalkenyl, (C₃-C₄)-haloalkynyl,     (C₃-C₆)-cycloalkyl-(C₁-C₄)-alkyl or represent an optionally     substituted C₃- to C₆-membered carbocyclic group; -   L¹ particularly preferably represents sulfur; L¹ particularly     preferably represents —N(R¹) where R¹ represents hydrogen, methyl,     ethyl, n-propyl, isopropyl, allyl, propargyl, cyclopropylmethyl or     cyclopropyl; -   L¹ preferably represents —C(R¹¹, R¹²)— where R¹¹, R¹² each     independently of one another represent halogen, (C₁-C₆)-haloalkyl or     (C₁-C₆)-alkoxy; -   L¹ particularly preferably represents —C(R¹¹, R¹²)— where R¹¹, R¹²     independently of one another represent fluorine, trifluoromethyl,     methoxy;     and salts, N-oxides and tautomeric forms of the compounds of the     formula (I).

In a further embodiment, compounds of the formula (I) are compounds

in which L¹, L³, Q, W, X and Y are as defined above and

-   L² preferably represents C(R²¹, R²²), where R²¹ and R²² each     independently of one another represent hydrogen, fluorine or     optionally mono- or poly-M²-substituted (C₁-C₄)-alkyl,     (C₃-C₄)-alkenyl, (C₃-C₄)-alkynyl, (C₁-C₄)-haloalkyl,     (C₃-C₄)-haloalkenyl, (C₃-C₄)-haloalkynyl, (C₁-C₄)-alkoxy,     (C₃-C₄)-alkenyloxy, (C₃-C₄)-alkynyloxy,     (C₃-C₆)-cycloalkyl-(C₁-C₄)-alkyl or represents an optionally     substituted C₃- to C₆-membered carbocyclic group, or where R²¹ and     R²² together represent an optionally substituted spiro-linked 3- to     6-membered cyclic group; -   L² particularly preferably represents C(R²¹, R²²) where R²¹ and R²²     each independently of one another represent hydrogen, fluorine,     methyl, ethyl, n-propyl, isopropyl, allyl, propargyl, methoxy,     ethoxy, allyloxy, propargyloxy, cyclopropylmethyl, cyclopropyl, or     where C(R²¹, R²²) represents spiro-C(CH₂—CH₂);     and salts, N-oxides and tautomeric forms of the compounds of the     formula (I).

In a further embodiment, compounds of the formula (I) are compounds

in which L¹, L², Q, W, X and Y are as defined above and

-   L³ preferably represents C(R³¹, R³²), where R³¹ and R³² each     independently of one another represent hydrogen or optionally mono-     or poly-M²-substituted (C₁-C₄)-alkyl, (C₃-C₄)-alkenyl,     (C₃-C₄)-alkynyl, (C₁-C₄)-haloalkyl, (C₃-C₄)-haloalkenyl,     (C₃-C₄)-haloalkynyl, (C₁-C₄)-alkoxy, (C₃-C₄)-alkenyloxy,     (C₃-C₄)-alkynyloxy, (C₃-C₆)-cycloalkyl-(C₁-C₄)-alkyl or represents     an optionally substituted C₃- to C₆-membered carbocyclic group, or     where R³¹ and R³² together represent an optionally substituted     spiro-linked 3- to 6-membered cyclic group; -   L³ particularly preferably represents C(R³¹, R³²) where R³¹ and R³²     each independently of one another represent hydrogen, methyl, ethyl,     n-propyl, isopropyl, allyl, propargyl, methoxy, ethoxy, allyloxy,     propargyloxy, cyclopropylmethyl, cyclopropyl, or where C(R³¹, R³²)     represents spiro-C(CH₂—CH₂); -   L³ preferably and particularly preferably represents a direct bond     between L² and N—Y;     and salts, N-oxides and tautomeric forms of the compounds of the     formula (I).

In a further embodiment, compounds of the formula (I) are compounds

in which L¹, L², W, X and Y are as defined above and

-   Q preferably represents mono- or poly-M¹-substituted phenyl,     pyridyl, thienyl, furanyl or isothiazolyl; -   Q particularly preferably represents mono- or poly-M¹-substituted     phenyl; -   Q very particularly preferably represents mono- or     poly-M¹-substituted phenyl where the phenyl may not be substituted     by trifluoromethyl in the 2-position; -   L³ preferably represents C(R³¹, R³²), where R³¹ and R³² each     independently of one another represent hydrogen or optionally mono-     or poly-M²-substituted (C₁-C₄)-alkyl, (C₃-C₄)-alkenyl,     (C₃-C₄)-alkynyl, (C₁-C₄)-haloalkyl, (C₃-C₄)-haloalkenyl,     (C₃-C₄)-haloalkynyl, (C₁-C₄)-alkoxy, (C₃-C₄)-alkenyloxy,     (C₃-C₄)-alkynyloxy, (C₃-C₆)-cycloalkyl-(C₁-C₄)-alkyl or represents     an optionally substituted C₃- to C₆-membered carbocyclic group, or     where R³¹ and R³² together represent an optionally substituted     spiro-linked 3- to 6-membered cyclic group; -   L³ particularly preferably represents C(R³¹, R³²) where R³¹ and R³²     each independently of one another represent hydrogen, methyl, ethyl,     n-propyl, isopropyl, allyl, propargyl, methoxy, ethoxy, allyloxy,     propargyloxy, cyclopropylmethyl, cyclopropyl; -   L³ particularly preferably represents C(R³¹, R³²) where R³¹ and R³²     each independently of one another represent methyl, ethyl, n-propyl,     isopropyl, allyl, propargyl, methoxy, ethoxy, allyloxy,     propargyloxy, cyclopropylmethyl, cyclopropyl;     and salts, N-oxides and tautomeric forms of the compounds of the     formula (I).

In a very particularly preferred further embodiment, compounds of the formula (I) are compounds

in which

-   X mono- or poly-M¹-substituted phenyl where M¹ is selected from the     group consisting of hydrogen, fluorine, bromine, chlorine, iodine,     cyano, nitro, OH, methyl, ethyl, isopropyl, tert-butyl,     trifluoromethyl, difluoromethyl, methoxy, ethoxy, isopropoxy,     trifluoromethoxy, difluoromethoxy, methylthio, trifluoromethylthio,     difluoromethylthio, 2,2,2-trifluoroethylthio, methylsulfonyl,     ethylsulfonyl, trifluoromethylsulfonyl,     2,2,2-trifluoroethylsulfonyl, methylsulfanyl, ethylsulfanyl,     trifluoromethylsulfanyl, 2,2,2-trifluoroethylsulfanyl and phenoxy; -   X represents 2-thienyl which is mono- or polysubstituted by M¹     selected from the group consisting of hydrogen, fluorine, chlorine,     bromine, iodine, methyl and trifluoromethyl; -   X represents 3-thienyl which is mono- or polysubstituted by M¹     selected from the group consisting of hydrogen, fluorine, chlorine,     bromine, iodine, methyl and trifluoromethyl; -   X represents 2-furanyl which is mono- or polysubstituted by M¹     selected from the group consisting of hydrogen, fluorine, chlorine,     bromine, iodine, methyl and trifluoromethyl; -   X represents 3-furanyl which is mono- or polysubstituted by M¹     selected from the group consisting of hydrogen, fluorine, chlorine,     bromine, iodine, methyl and trifluoromethyl; -   Q represents 2-thienyl, 3-fluoro-2-thienyl, 3-chloro-2-thienyl,     3,4-dichloro-2-thienyl, 3,4,5-trichloro-2-thienyl,     3-bromo-2-thienyl, 3-iodo-2-thienyl, 3-cyano-2-thienyl,     3-methyl-2-thienyl, 3-(trifluoromethyl)-2-thienyl,     3-methoxy-2-thienyl, 3-ethoxy-2-thienyl, 3-thienyl,     2-fluoro-3-thienyl, 2-chloro-3-thienyl, 2-bromo-3-thienyl,     2-iodo-3-thienyl, 2-cyano-3-thienyl, 2-methyl-3-thienyl,     2-(trifluoromethyl)-3-thienyl, 2-methoxy-3-thienyl,     2-ethoxy-3-thienyl, 2-furanyl, 3-fluoro-2-furanyl,     3-chloro-2-furanyl, 3-bromo-2-furanyl, 3-iodo-2-furanyl,     3-cyano-2-furanyl, 3-methyl-2-furanyl,     3-(trifluoromethyl)-2-furanyl, 3-methoxy-2-furanyl,     3-ethoxy-2-furanyl, 3-furanyl, 2-chloro-3-furanyl,     2-bromo-3-furanyl, 2-iodo-3-furanyl, 2-cyano-3-furanyl,     2-methyl-3-furanyl, 2-(trifluoromethyl)-3-furanyl,     2-methoxy-3-furanyl, 2-ethoxy-3-furanyl, 4-chloro-5-isothiazolyl,     3,4-dichloro-5-isothiazolyl, 2-fluorophenyl, 2,6-difluorophenyl,     2-chlorophenyl, 2,6-dichlorophenyl, 2-bromophenyl, 2-iodophenyl,     2-(difluoromethyl)phenyl, 2-(trifluoromethyl)phenyl,     2-chloro-3-pyridyl, 3-chloro-2-pyridyl or     2-(trifluoromethyl)-3-pyridyl; -   Y represents hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl,     sec-butyl, isobutyl, tert-butyl, cyanomethyl, 2,2-difluoroethyl,     2,2,2-trifluoroethyl, allyl, butenyl, propargyl, butynyl,     3,3-dichloroprop-2-enyl, methoxy, ethoxy, cyclopropylmethyl,     cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; -   W represents oxygen; -   L¹ represents —N(R¹) where R² represents hydrogen, methyl, ethyl,     n-propyl, isopropyl, allyl, propargyl, cyclopropylmethyl or     cyclopropyl; -   L² represents C(R²¹, R²²) where R²¹ and R²² each independently of     one another represent hydrogen, fluorine, methyl, ethyl, n-propyl,     isopropyl, allyl, propargyl, methoxy, ethoxy, allyloxy,     propargyloxy, cyclopropylmethyl, cyclopropyl, or where C(R²¹, R²²)     represents spiro-C(CH₂—CH₂); -   L³ represents a direct bond between L² and N—Y.

In a very particularly preferred further embodiment, compounds of the formula (I-b) are compounds

in which L², L³, Q, W and Y are as defined above and

-   M¹ and M³ independently of one another represent halogen, cyano,     nitro, OH, (C₁-C₁₀)-alkyl, (C₁-C₁₀)-haloalkyl, (C₁-C₁₀)-alkoxy,     (C₁-C₁₀)-haloalkoxy, (C₁-C₁₀)-alkylthio, (C₁-C₁₀)-haloalkylthio,     (C₁-C₁₀)-alkylsulfonyl, (C₁-C₁₀)-haloalkylsulfonyl,     (C₁-C₁₀)-alkylsulfanyl, (C₁-C₁₀)-haloalkylsulfanyl, (3- to     14-membered cyclic group)-O—.

Novel are the compounds of the formula (I-a)

in which M¹ represents chlorine, bromine or iodine and L¹, L², L³, X and Y are as defined above.

Novel are the compounds of the formula I-2

in which L¹, L², L³, X and Y are as defined above.

Novel are the compounds of the formula I-3

in which L¹, L², L³, X and Y are as defined above.

Novel are the compounds of the formula I-4

in which L¹, L², L³, X and Y are as defined above.

Preparation Process A

The radicals X, Y, L¹, L², L³ and Q have the meanings described above. W in this case represents oxygen.

Compounds of the general formula (a) according to the invention can be prepared from amines of the formula (a1) and carboxylic acids of the formula (a2) or halides thereof of the formula (a3) by generally known processes as described, for example, in WO-A 2007/060166. The amines of the formula (a1) and carboxylic acids of the formula (a2) and their halides of the formula (a3) are commercially available.

Preparation Process A-1

The compounds of the formula (I-a)

in which M¹ represents chlorine, bromine or iodine and L¹, L², L³, X and Y are as defined above are prepared by reacting amines of the formula (a1)

where X, Y, L¹, L², L³ have the meanings described above with carboxylic acids of the formula (a2-1)

where M¹ represents chlorine, bromine or iodine, or their acid halides of the formula (a3-1)

where M¹ represents chlorine, bromine or iodine and Hal represents fluorine, chlorine or bromine, to give the compounds of the formula (I-a).

The amines of the formula (a1) and carboxylic acids of the formula (a2-1) and their halides of the formula (a3-1) are commercially available. Alternatively, the halides of the formula (a3-1) can be prepared by generally known methods from carboxylic acids of the formula (a2-1) using appropriate halogenating agents, for example phosphoryl chloride, phosphoryl bromide, thionyl chloride, oxalyl chloride or phosgene.

When using carbonyl halides of the general structure (a3-1), the compounds of the general formula (I-a) according to the invention are advantageously carried out in the presence of a reaction auxiliary. Suitable reaction auxiliaries are all customary inorganic or organic bases. These include, for example, alkaline earth metal or alkali metal hydrides, hydroxides, amides, alcoholates, acetates, carbonates or hydrogencarbonates, such as, for example, sodium hydride, sodium amide, sodium methoxide, sodium ethoxide, potassium tert-butoxide, sodium hydroxide, potassium hydroxide, ammonium hydroxide, sodium acetate, potassium acetate, calcium acetate, ammonium acetate, sodium carbonate, potassium carbonate, potassium hydrogencarbonate or ammonium carbonate, and also tertiary amines, such as, for example, trimethylamine, triethylamine, diisopropylethylamine, tributylamine, N,N-dimethylaniline, pyridine, N-methylpiperidine, 4-(N,N-dimethylamino)pyridine, diazabicyclooctane (DABCO), diazabicyclononene (DBN) or diazabicycloundecene (DBU), in particular triethylamine.

When using carboxylic acids of the general structure (a2-1), the compounds of the general formula (I-a) according to the invention are advantageously carried out in the presence of a condensing agent. The carboxylic acids are commercially available. Suitable condensing agents are especially dehydrating chemicals. These preferably include acid anhydrides and acid halides, such as, for example, acetic anhydride, propionic anhydride, phosphorus(V) oxide, phosphoryl chloride, phosphoryl bromide, phosphorus trichloride, phosphorus tribromide, thionyl chloride, oxalyl chloride, phosgene, diphosgene, methyl formate, ethyl formate, and also carbodiimides such as, for example, N,N′-dicyclohexylcarbodiimide (DCC) or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC-HCl). Other known condensing agents are triphenylphosphine/carbon tetrachloride, 4-(4,6-dimethoxy[1.3.5]triazin-2-yl)-4-methylmorpholinium chloride hydrate or hydroxybenzotriazole (HOBt). Particular mention may be made here of the combination of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC-HCl) and hydroxybenzotriazole (HOBt).

The compounds of the general formula (I-a) according to the invention are optionally prepared using one or more diluents. Suitable diluents are especially inert organic solvents. These include in particular aliphatic, alicyclic or aromatic, optionally halogenated hydrocarbons such as, for example, benzine, benzene, toluene, xylene, chlorobenzene, dichlorobenzene, petroleum ether, hexane, cyclohexane, dichloromethane, chloroform, carbon tetrachloride, tetrahydrofuran, dioxane, acetonitrile or dimethylformamide.

When carrying out process A-1, the reaction temperatures can be varied within a relatively wide range. In general, the process is carried out at temperatures between 0° C. and 150° C., preferably between 10° C. and 120° C.

Process A-1 is generally carried out under atmospheric pressure. However, it is also possible to carry out process A-1 under elevated or reduced pressure—generally between 0.1 bar and 10 bar.

Preparation Process B

The radicals X, L¹, L², L³, and Q have the meanings described above. In this case, W represents oxygen,

Y represents hydrogen.

Compounds of the general structure (I) or their embodiment (b) according to the invention can be prepared from amines of the formula (b1) and carboxylic acids of the formula (a2) or halides thereof of the formula (a3) by generally known processes as described, for example, in EP2007060166. The amines of the formula (b1) and carboxylic acids of the formula (a2) and their halides of the formula (a3) are commercially available.

Preparation Process C

The radicals X, Y, L¹, L², L³ and Q have the meanings described above. In this case, W represents oxygen, AG represents a leaving group, for example halogens or alkyl- or arylsulfonates.

Compounds of the general formula (I) according to the invention and their embodiment (a) can be prepared from amines of the formula (b) and alkylating agents of the formula (c1) by generally known processes as described, for example, in EP2007060166.

Preparation Process D

The radicals X, Y, L¹, L², L³ and Q have the meanings described above. W=oxygen is transformed directly into W=sulfur.

Compounds of the general formula (I) according to the invention and their embodiment (d) can be prepared from compounds of the formula (a) and appropriate sulfurizing agents, for example tetraphosphorus decasulfide (“phosphorus pentasulfide”) or 2,4-bis[4-methoxyphenyl]-2,4-dithiono-1,2,3,4-dithiadiphosphetane (“Lawesson's reagent”), by generally known processes. Process examples are known inter alia from Houben-Weyl, Methoden der Organischen Chemie [Methods of Organic Chemistry], E5, 1255 (Thieme Verlag, Stuttgart, 1985).

A further aspect of the present invention is a method for controlling endoparasitic pests, which method is characterized in that a compound of the formula (I) or (I-a) according to the invention or a salt, N-oxide or tautomeric form thereof is allowed to act on the pests and/or their habitat.

Field of Anthelmintic Use

The compositions according to the invention, having favorable homeotherm toxicity, are suitable for controlling pathogenic endoparasites which occur in humans and in animal keeping and animal breeding in the case of agricultural animals, breeding animals, zoo animals, laboratory animals, experimental animals and pets. They may be employed against all or individual stages of development of the pests and against resistant and normally sensitive endoparasite isolates. By controlling the pathogenic endoparasites, it is intended to reduce disease, mortality and decreasing performance (for example in the production of meat, milk, wool, hides, eggs, honey, etc.), so that more economical, simpler and healthier animal husbandry is possible by using the active compounds. The pathogenic endoparasites include helminths such as Platyhelmintha (in particular Monogenea, cestodes and trematodes), nematodes, Pentastoma and Acanthocephala. Examples which may be mentioned are:

Monogenea: for example: Gyrodactylus spp., Dactylogyrus spp., Polystoma spp.

Cestodes: From the order of the Pseudophyllidea, for example: Diphyllobothrium spp., Spirometra spp., Schistocephalus spp., Ligula spp., Bothridium spp., Diphlogonoporus spp.

From the order of the Cyclophyllidea, for example: Mesocestoides spp., Anoplocephala spp., Paranoplocephala spp., Moniezia spp., Thysanosoma spp., Thysaniezia spp., Avitellina spp., Stilesia spp., Cittotaenia spp., Andyra spp., Bertiella spp., Taenia spp., Echinococcus spp., Hydatigera spp., Davainea spp., Raillietina spp., Hymenolepis spp., Echinolepis spp., Echinocotyle spp., Diochis spp., Dipylidium spp., Joyeuxiella spp., Diplopylidium spp.

Trematodes: From the class of the Digenea, for example: Diplostomum spp., Posthodiplostomum spp., Schistosoma spp., Trichobilharzia spp., Ornithobilharzia spp., Austrobilharzia spp., Gigantobilharzia spp., Leucochloridium spp., Brachylaima spp., Echinostoma spp., Echinoparyphium spp., Echinochasmus spp., Hypoderaeum spp., Fasciola spp., Fasciolides spp., Fasciolopsis spp., Cyclocoelum spp., Typhlocoelum spp., Paramphistomum spp., Calicophoron spp-, Cotylophoron spp., Gigantocotyle spp., Fischoederius spp., Gastrothylacus spp., Notocotylus spp., Catatropis spp., Plagiorchis spp., Prosthogonimus spp., Dicrocoelium spp., Eurytrema spp., Troglotrema spp., Paragonimus spp., Collyriclum spp., Nanophyetus spp., Opisthorchis spp., Clonorchis spp. Metorchis spp., Heterophyes spp., Metagonimus spp.

Nematodes: From the order of the Trichinellida, for example: Trichuris spp., Capillaria spp., Trichomosoides spp., Trichinella spp.

From the order of the Tylenchida, for example: Micronema spp., Strongyloides spp.

From the order of the Rhabditina, for example: Strongylus spp., Triodontophorus spp., Oesophagodontus spp., Trichonema spp., Gyalocephalus spp., Cylindropharynx spp., Poteriostomum spp., Cyclococercus spp., Cylicostephanus spp., Oesophagostomum spp., Chabertia spp., Stephanurus spp., Ancylostoma spp., Uncinaria spp., Bunostomum spp., Globocephalus spp., Syngamus spp., Cyathostoma spp., Metastrongylus spp., Dictyocaulus spp., Muellerius spp., Protostrongylus spp., Neostrongylus spp., Cystocaulus spp., Pneumostrongylus spp., Spicocaulus spp., Elaphostrongylus spp. Parelaphostrongylus spp., Crenosoma spp., Paracrenosoma spp., Angiostrongylus spp., Aelurostrongylus spp., Filaroides spp., Parafilaroides spp., Trichostrongylus spp., Haemonchus spp., Ostertagia spp., Marshallagia spp., Cooperia spp., Nematodirus spp., Hyostrongylus spp., Obeliscoides spp., Amidostomum spp., Ollulanus spp.

From the order of the Spirurida, for example: Oxyuris spp., Enterobius spp., Passalurus spp., Syphacia spp., Aspiculuris spp., Heterakis spp.; Ascaris spp., Toxascaris spp., Toxocara spp., Baylisascaris spp., Parascaris spp., Anisakis spp., Ascaridia spp.; Gnathostoma spp., Physaloptera spp., Thelazia spp., Gongylonema spp., Habronema spp., Parabronema spp., Draschia spp., Dracunculus spp.; Stephanofilaria spp., Parafilaria spp., Setaria spp., Loa spp., Dirofilaria spp., Litomosoides spp., Brugia spp., Wuchereria spp., Onchocerca spp.

Acantocephala: From the order of the Oligacanthorhynchida, for example: Macracanthorhynchus spp., Prosthenorchis spp.; from the order of the Polymorphida, for example: Filicollis spp.; from the order of the Moniliformida, for example: Moniliformis spp.

From the order of the Echinorhynchida, for example, Acanthocephalus spp., Echinorhynchus spp., Leptorhynchoides spp.

Pentastoma: From the order of the Porocephalida, for example, Linguatula spp.

According to a preferred embodiment, the compounds of the formula (I) are used for controlling nematodes. The following nematodes may be mentioned with particular preference: Trichinellida, Tylenchida, Rhabditina or the following from the order of the Spirurida: Gnathostoma spp., Physaloptera spp., Thelazia spp., Gongylonema spp., Habronema spp., Parabronema spp., Draschia spp., Dracunculus spp.

A further particularly preferred embodiment provides the use for controlling Strongylida, in particular Haemonchus spp. (e.g. Haemonchus contortus), Trichostrongylus spp. (e.g. Trichostrongylus colubriformis), Cooperia spp., and Ostertagia spp. or Teladorsagia spp.

A further particularly preferred embodiment provides the use for controlling Ascaridida such as, for example, Parascaris spp.

Animals can be fish, reptiles, birds or in particular mammals.

The agricultural and breeding livestock include mammals such as, for example, cattle, horses, sheep, pigs, goats, camels, water buffalo, donkeys, rabbits, fallow deer, reindeer, fur-bearing animals such as, for example, mink, chinchilla, raccoon, birds such as, for example, chicken, geese, turkeys, ducks, ostriches, fish such as trout, salmon, carp, perches, pikes, eels.

Laboratory and experimental animals include mice, rats, guinea pigs, golden hamsters, dogs and cats.

Pets include dogs and cats.

According to the invention, the use for animals is preferred; however, in principle, the use for humans is also possible. In humans, Ascaris spp., Ancylostoma spp, Necator spp., Trichuris spp., Strongyloides spp. and Enterobius spp. are controlled with preference.

According to one embodiment, from among the mammals, herbivores, that is animals living mainly off plants, are preferred for the use according to the invention. Particular preference is given to the treatment of ruminants (such as, for example, sheep, goats, cattle).

A preferred example of a non-ruminating mammalian herbivore are horses. Here, the above-mentioned combinations can preferably be employed, for example, for controlling Strongylida or in particular Ascaridida such as Parascaris equorum.

In the case of the ruminants, preference is given to controlling Strongylida, in particular Haemonchus spp., Trichostrongylus spp., Cooperia spp. and Ostertagia spp.

According to the invention, particular preference is given to treating sheep.

According to the invention, particular preference is likewise given to treating cattle.

The active compounds according to the invention are employed in the veterinary sector and in animal husbandry in a manner known per se directly or in the form of suitable preparations. Administration can be effected prophylactically as well as therapeutically.

The compounds of the general formula (I) or (I-a) can be employed on their own or in combination with other active compounds, for example with other parasiticides.

The examples below illustrate the invention without limiting it.

PREPARATION EXAMPLES Example 14-11

94.6 mg (0.75 mmol) of 2-methylfuran-3-carboxylic acid, 198 mg (0.90 mmol) of 2-(4-chlorophenyl)-2-methylpropane-1-amine, 50.6 mg (0.37 mmol) of 1-hydroxybenzotriazole (HOBt), 46 mg (0.37 mmol) of DMAP, 172.5 mg (0.90 mmol) of EDC hydrochloride and 116 mg (0.90 mmol) of diisopropylethylamine are dissolved in 10 ml of dichloromethane, and the solution is stirred at room temperature for 16 h. After the reaction has ended, 10 ml of water are added, the organic phase is separated off and the aqueous phase is re-extracted with 5 ml of dichloromethane. The dichloromethane phases are filtered through a sodium sulfate/silica gel cartridge, the solvent is evaporated and the residue is separated by preparative HPLC.

Yield: 139.3 mg (63.6% of theory), colorless solid.

¹H-NMR (d6-DMSO): δ [ppm], 7.73 (t, 1H, NH), 7.48 (d, 1H), 7.42 (d, 2H), 7.35 (d, 2H), 6.80 (d, 1H), 3.37 (d, 2H), 2.43 (s, 3H), 1.26 (s, 6H).

Example 20-238

114 mg (0.6 mmol) of 2-(2-chloro-4-(trifluoromethyl)phenoxy)-1-ethylamine, 163 mg (0.72 mmol) of 2-(trifluoromethyl)nicotinoyl chloride, 40.5 mg (0.3 mmol) of 1-hydroxybenzotriazole (HOBt), 36.6 mg (0.3 mmol) of DMAP, 115 mg (0.6 mmol) of EDC hydrochloride and 77.5 mg (0.6 mmol) of diisopropylethylamine are dissolved in 10 ml of dichloromethane, and the solution is stirred at room temperature for 16 h. After the reaction has ended, 10 ml of water are added, the organic phase is separated off and the aqueous phase is re-extracted with 5 ml of dichloromethane. The dichloromethane phases are filtered through a sodium sulfate/silica gel cartridge, the solvent is evaporated and the residue is separated by preparative HPLC.

Yield: 146 mg (59.9% of theory), colourless solid.

¹H-NMR (d6-DMSO): δ [ppm], 8.95 (t, 1H, NH), 8.80-8.79 (d, 1H), 7.99-7.97 (d, 1H), 7.84 (s, 1H), 7.80-7.77 (dd, 1H), 7.72-7.69 (d, 1H), 7.40-7.38 (d, 1H), 4.30 (t, 2H), 3.70-3.67 (quart, 2H).

The examples listed in the table below can be prepared in the same manner.

¹H NMR Data

The ¹H NMR data were determined with a Bruker Avance 400 equipped with a flow probe head (volume 60 μl), with tetramethylsilane as a reference (0.0) and the solvents CD₃CN, CDCl₃, D₆-DMSO.

The NMR data for selected examples are listed either in conventional form (δ values, multiplet splitting, number of hydrogen atoms) or as NMR peak lists.

NMR peak list method: When the ¹H NMR data for selected examples are noted in the form of ¹H NMR peak lists, first the δ value in ppm and then the signal intensity is listed for each signal peak, separated by a space. The δ value—signal intensity number pairs for different signal peaks are listed with separation from one another by semicolons. The peak list for one example therefore takes the form of: δ₁ (intensity₁); δ₂ (intensity₂); . . . ; δ_(i) (intensity_(i)); . . . ; δ_(n) (intensity_(n)) The solvent in which the NMR spectrum was recorded is listed in square brackets before the NMR peak list or the conventional NMR interpretation list.

Lengthy table referenced here US20140323736A1-20141030-T00001 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00002 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00003 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00004 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00005 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00006 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00007 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00008 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00009 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00010 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00011 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00012 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00013 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00014 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00015 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00016 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00017 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00018 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00019 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00020 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00021 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00022 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00023 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00024 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00025 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20140323736A1-20141030-T00026 Please refer to the end of the specification for access instructions.

Biological Experiments Example A Nippostrongylus brasiliensis test (NIPOBR)

Test Method for In Vitro Experiments with Nippostrongylus brasiliensis

Adult Nippostrongylus brasiliensis were isolated from the small intestine of female Wistar rats and transferred into 0.9% NaCl containing 20 g/ml sisomycin and 2 g/ml Canesten. The incubation of the worms (both sexes) was carried out in 1.0 ml of the medium also used for determining the acetylcholinesterase activity. The compounds were dissolved in DMSO and added to the incubation medium such that final concentrations of 100, 10 and 1 g/ml, respectively, were present. The controls contained only DMSO. Incubation and enzyme determination were described in the study by Rapson et al. (1987) Z. Parasitenkunde 73, 190-191.

Efficacy was classified using the categories 35 (0-35% inhibition), 60 (>35-60%), 84 (>60-84%) and 100 (>84-100%).

Example number Efficacy at 10 μg/ml 1-2  100% 1-7  100% 1-14 100% 1-20 100% 1-22 100% 2-3  100% 2-7  100% 2-8  100% 2-9  100% 2-11 100% 2-12 100% 2-16 100% 2-19 100% 2-20 100% 2-23 100% 3-4  100% 3-9  100% 3-11 100% 3-14 100% 3-15 100% 3-19 100% 3-20 100% 3-21 100% 4-3  100% 4-5  100% 6-7  100% 13-4  100% 14-4  100% 20-22  100%

Example B In Vivo Nematode Test

Heligmosomoides polygyrus/Mouse

Mice experimentally infected with Heligmosomoides polyvgyrus were treated after the prepatency time of the parasite had passed. The active compounds were administered orally in a Cremophor EL/water mixture.

The degree of activity was determined by counting the number of worms in the intestine during the dissection of the mice. The efficacy was determined via the number of worms compared to the number of worms in the intestine of untreated control animals.

Active compounds tested and effective dosages (Dosis effectiva) are shown in the table below.

Substance Efficacy at 100 mg/kg 4-3 100% 13-4  100% 14-2  100% 17-37 100%

Example C In Vivo Nematode Test

Haemonchus contortus/Sheep

Sheep experimentally infected with Haemonchus contortus were treated after the prepatency time of the parasite had passed. The active compounds were administered orally and/or intramuscularly as pure active compound.

The degree of activity was determined by counting the number of worms in the abomasum during the dissection of the sheep. The efficacy was determined via the number of worms compared to the number of worms in the abomasum of untreated control animals.

Active compounds tested and effective dosages (Dosis effectiva) are shown in the table below.

Substance Dosage Efficacy 13-4  20 mg/kg  81% 14-4 100 mg/kg 100%

Example D Haemonchus contortus Test (HAEMCO)

Solvent: dimethyl sulfoxide

To produce a suitable preparation of active compound, 10 mg of active compound are mixed with 0.5 ml of dimethyl sulfoxide, and the concentrate is diluted with “Ringer solution” to the desired concentration. Vessels containing the active compound preparation of the desired concentration are populated with about 40 Haemonchus contortus larvae.

After 5 days, the kill in % is determined. 100% means that all larvae have been killed; 0% means that no larvae have been killed.

In this test, for example, the following compounds of the Preparation Examples show an effect of 100% at an application rate of 100 ppm: 20-26, 20-29

In this test, for example, the following compounds of the Preparation Examples show an effect of 90% at an application rate of 20 ppm: 13-4

In this test, for example, the following compounds of the Preparation Examples show an effect of 80% at an application rate of 20 ppm: 14-2, 14-4

Cooperia curticei Test (COOPCU)

Solvent: dimethyl sulfoxide

To produce a suitable preparation of active compound, 10 mg of active compound are mixed with 0.5 ml of dimethyl sulfoxide, and the concentrate is diluted with “Ringer solution” to the desired concentration. Vessels containing the active compound preparation of the desired concentration are populated with about 40 Cooperia curticei larvae.

After 5 days, the kill in % is determined. 100% means that all larvae have been killed; 0% means that no larvae have been killed.

In this test, for example, the following compounds of the Preparation Examples show an effect of 100% at an application rate of 100 ppm: 20-26

In this test, for example, the following compounds of the Preparation Examples show an effect of 80% at an application rate of 100 ppm: 17-37

In this test, for example, the following compounds of the Preparation Examples show an effect of 90% at an application rate of 20 ppm: 14-2, 14-4, 13-4

In this test, for example, the following compounds of the Preparation Examples show an effect of 80% at an application rate of 20 ppm: 20-29

LENGTHY TABLES The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20140323736A1). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3). 

1. A compound of formula (I)

in which X represents mono- or poly-M¹-substituted phenyl, thienyl or furanyl; Q represents mono- or poly-M¹-substituted pyridyl, thienyl, furanyl or isothiazolyl; Y represents hydrogen or represents optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₂-C₁₀)-alkenyloxy, (C₃-C₁₀)-alkynyloxy, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represents an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; W represents oxygen or sulfur; L¹ represents —C(R¹¹, R¹²)—, oxygen, sulfur or —N(R¹)—; L² represents —C(R²¹, R²²)—; L³ represents —C(R³¹, R³²)— or a direct bond; M¹ represents hydrogen, halogen, cyano, nitro, OH, (C₁-C₁₀)-alkyl, (C₁-C₁₀)-haloalkyl, (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-haloalkoxy, (C₁-C₁₀)-alkylthio, (C₁-C₁₀)-haloalkylthio, (C₁-C₁₀)-alkylsulfonyl, (C₁-C₁₀)-haloalkylsulfonyl, (C₁-C₁₀)-alkylsulfanyl, (C₁-C₁₀)-haloalkylsulfanyl, (3- to 14-membered cyclic group)-O—; R¹ represents hydrogen or optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₃-C₁₀)-cycloalkyl-(C₁-C₁₀)-alkyl or represents an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; R¹¹, R¹² each independently of one another represent hydrogen, halogen or optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₂-C₁₀)-alkenyloxy, (C₃-C₁₀)-alkynyloxy, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represents an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; R¹¹, R¹² together represent an optionally mono- or poly-M²-substituted spiro-attached 3- to 14-membered carbo- or 3- to 10-membered heterocyclic group; R²¹, R²² each independently of one another represent hydrogen, halogen or optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-haloalkoxy, (C₂-C₁₀)-alkenyloxy, (C₃-C₁₀)-alkynyloxy, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represent an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; R²¹, R²² together represent an optionally mono- or poly-M²-substituted spiro-attached 3- to 14-membered carbo- or 3- to 10-membered heterocyclic group; R³¹, R³² each independently of one another represent hydrogen or optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represent an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; R³¹, R³² together represent an optionally mono- or poly-M²-substituted spiro-attached 3- to 14-membered carbo- or 3- to 10-membered heterocyclic group; M² each independently of one another represent halogen, formyl, cyano, nitro, (C₁-C₁₀)-alkyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-alkynyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-haloalkoxy, (C₂-C₁₀)-alkenyloxy, (C₂-C₁₀)-haloalkenyloxy, (C₃-C₁₀)-alkynyloxy, (C₃-C₁₀)-haloalkynyloxy, (C₁-C₁₀)-alkylthio, (C₁-C₁₀)-haloalkylthio, (C₂-C₁₀)-alkenylthio, (C₂-C₁₀)-haloalkenylthio, (C₃-C₁₀)-alkynylthio, (C₃-C₁₀)-haloalkynylthio, (C₁-C₁₀)-alkylsulfonyl, (C₁-C₁₀)-haloalkylsulfonyl, (C₂-C₁₀)-alkenylsulfonyl, (C₂-C₁₀)-haloalkenylsulfonyl, (C₃-C₁₀)-alkynylsulfonyl, (C₃-C₁₀)-haloalkynylsulfonyl, (C₁-C₁₀)-alkylsulfanyl, (C₁-C₁₀)-haloalkylsulfanyl, (C₂-C₁₀)-alkenylsulfanyl, (C₂-C₁₀)-haloalkenylsulfanyl, (C₃-C₁₀)-alkynylsulfanyl, (C₃-C₁₀)-haloalkynylsulfanyl, (C₁-C₁₀)-alkylcarbonyl, (C₁-C₁₀)-haloalkylcarbonyl, (C₂-C₁₀)-alkenylcarbonyl, (C₂-C₁₀)-haloalkenylcarbonyl, (C₂-C₁₀)-alkynylcarbonyl, (C₂-C₁₀)-haloalkynylcarbonyl, (C₁-C₁₀)-alkoxycarbonyl, (C₁-C₁₀)-haloalkoxycarbonyl, (C₂-C₁₀)-alkenyloxycarbonyl, (C₂-C₁₀)-haloalkenyloxycarbonyl, (C₃-C₁₀)-alkynyloxycarbonyl, (C₃-C₁₀)-haloalkynyloxycarbonyl, (C₁-C₁₀)-alkylcarbonyloxy, (C₁-C₁₀)-haloalkylcarbonyloxy, (C₂-C₁₀)-alkenylcarbonyloxy, (C₂-C₁₀)-haloalkenylcarbonyloxy, (C₂-C₁₀)-alkynylcarbonyloxy, (C₂-C₁₀)-haloalkynylcarbonyloxy, a 3- to 14-membered cyclic group; And/or a salt, N-oxide and/or tautomeric form thereof; capable of being used as medicament for controlling one or more endoparasites in an animal and/or human.
 2. A compound as claimed in claim 1 where X represents mono- or poly-M¹-substituted phenyl, 2-thienyl, 3-thienyl, 2-furanyl or 3-furanyl; Q represents mono- or poly-M¹-substituted 2-thienyl, 3-thienyl, 2-furanyl, 5-isothiazolyl, 3-pyridyl or 2-pyridyl; Y represents hydrogen or represents optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₂-C₁₀)-alkenyloxy, (C₃-C₁₀)-alkynyloxy, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represents an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; L¹ represents —C(R¹¹, R¹²)—, oxygen or —N(R¹)—; M¹ represents hydrogen, halogen, cyano, nitro, OH, (C₁-C₆)-alkyl, (C₁-C₆)-haloalkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-haloalkoxy, (C₁-C₆)-alkylthio, (C₁-C₆)-haloalkylthio, (C₁-C₆)-alkylsulfonyl, (C₁-C₆)-haloalkylsulfonyl, (C₁-C₆)-alkylsulfanyl, (C₁-C₆)-haloalkylsulfanyl, (C₃-C₁₄)-cycloalkyl-O—, (C₃-C₁₄)-cycloalkenyl-O—, (C₆-C₁₄)-aryl-O—, halogenated (C₃-C₁₄)-cycloalkyl-O—, halogenated (C₃-C₁₄)-cycloalkenyl-O—, halogenated (C₆-C₁₄)-aryl-O—; R¹ represents hydrogen or optionally mono- or poly-M²-substituted (C₁-C₄)-alkyl, (C₂-C₄)-alkenyl, (C₂-C₄)-alkynyl, (C₁-C₄)-haloalkyl, (C₂-C₄)-haloalkenyl, (C₂-C₄)-haloalkynyl, (C₃-C₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represents optionally mono- or poly-M²-substituted (C₃-C₈)-cycloalkyl or halogenated (C₃-C₈)-cycloalkyl; R¹¹, R¹² each independently of one another represent hydrogen, fluorine or optionally mono- or poly-M²-substituted (C₁-C₆)-alkyl, (C₁-C₆)-haloalkyl, (C₁-C₆)-alkoxy, (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl or halogenated (C₃-C₈)-cycloalkyl; R¹¹, R¹² represent C(R¹¹, R¹²) as spiro-C(CH₂—CH₂); R²¹, R²² each independently of one another represent hydrogen, fluorine or optionally mono- or poly-M²-substituted (C₁-C₄)-alkyl, (C₂-C₄)-alkenyl, (C₂-C₄)-alkynyl, (C₁-C₄)-haloalkyl, (C₂-C₄)-haloalkenyl, (C₂-C₄)-haloalkynyl, (C₁-C₆)-alkoxy, (C₁-C₄)-haloalkoxy, (C₂-C₄)-alkenyloxy, (C₃-C₄)-alkynyloxy, (C₃-C₄)-cycloalkyl-(C₁-C₄)-alkyl, (C₃-C₈)-cycloalkyl or halogenated (C₃-C₈)-cycloalkyl; R²¹, R²² represent C(R²¹, R²²) as spiro-C(CH₂—CH₂); R³¹, R³² each independently of one another represent hydrogen or optionally mono- or poly-M²-substituted (C₁-C₄)-alkyl, (C₂-C₄)-alkenyl, (C₂-C₄)-alkynyl, (C₁-C₄)-haloalkyl, (C₂-C₄)-haloalkenyl, (C₂-C₄)-haloalkynyl, (C₁-C₆)-alkoxy, (C₁-C₄)-haloalkoxy, (C₂-C₄)-alkenyloxy, (C₃-C₄)-alkynyloxy, (C₃-C₄)-cycloalkyl-(C₁-C₄)-alkyl or represent an optionally mono- or poly-M²-substituted (C₃-C₈)-cycloalkyl or halogenated (C₃-C₈)-cycloalkyl; R³¹, R³² represent C(R³¹, R³²) as spiro-C(CH₂—CH₂); M² each independently of one another represent halogen, formyl, cyano, nitro, (C₁-C₄)-alkyl, (C₁-C₄)-haloalkyl, (C₂-C₄)-alkenyl, (C₂-C₄)-haloalkenyl, (C₂-C₄)-alkynyl, (C₂-C₄)-haloalkynyl, (C₁-C₄)-alkoxy, (C₁-C₄)-haloalkoxy, (C₂-C₄)-alkenyloxy, (C₂-C₄)-haloalkenyloxy, (C₃-C₄)-alkynyloxy, (C₃-C₄)-haloalkynyloxy, (C₁-C₄)-alkylthio, (C₁-C₄)-haloalkylthio, (C₂-C₄)-alkenylthio, (C₂-C₄)-haloalkenylthio, (C₃-C₄)-alkynylthio, (C₃-C₄)-haloalkynylthio, (C₁-C₄)-alkylsulfonyl, (C₁-C₄)-haloalkylsulfonyl, (C₂-C₄)-alkenylsulfonyl, (C₂-C₄)-haloalkenylsulfonyl, (C₃-C₄)-alkynylsulfonyl, (C₃-C₄)-haloalkynylsulfonyl, (C₁-C₄)-alkylsulfanyl, (C₁-C₄)-haloalkylsulfanyl, (C₂-C₄)-alkenylsulfanyl, (C₂-C₄)-haloalkenylsulfanyl, (C₃-C₄)-alkynylsulfanyl, (C₃-C₄)-haloalkynylsulfanyl, (C₁-C₄)-alkylcarbonyl, (C₁-C₄)-haloalkylcarbonyl, (C₂-C₄)-alkenylcarbonyl, (C₂-C₄)-haloalkenylcarbonyl, (C₂-C₄)-alkynylcarbonyl, (C₂-C₄)-haloalkynylcarbonyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-haloalkoxycarbonyl, (C₂-C₄)-alkenyloxycarbonyl, (C₂-C₄)-haloalkenyloxycarbonyl, (C₃-C₄)-alkynyloxycarbonyl, (C₃-C₄)-haloalkynyloxycarbonyl, (C₁-C₄)-alkylcarbonyloxy, (C₁-C₄)-haloalkylcarbonyloxy, (C₂-C₄)-alkenylcarbonyloxy, (C₂-C₄)-haloalkenylcarbonyloxy, (C₂-C₄)-alkynylcarbonyloxy, (C₂-C₄)-haloalkynylcarbonyloxy or (C₃-C₆)-cycloalkyl; And/or a salt, N-oxide and/or tautomeric form thereof; capable of being used as medicament for controlling one or more endoparasites in an animal and/or human.
 3. The compound as claimed in claim 1 where X represents mono- to tri-M¹-substituted phenyl, 2-thienyl, 3-thienyl, 2-furanyl or 3-furanyl; Q represents mono- or di-M¹-substituted 2-thienyl, 3-thienyl, 2-furanyl, 5-isothiazolyl, 3-pyridyl or 2-pyridyl; Y represents hydrogen or represents optionally mono- or poly-M²-substituted (C₁-C₄)-alkyl, (C₂-C₄)-alkenyl, (C₃-C₄)-alkynyl, (C₁-C₄)-haloalkyl, (C₂-C₄)-haloalkenyl, (C₃-C₄)-haloalkynyl, (C₁-C₄)-alkoxy, (C₂-C₄)-alkenyloxy, (C₃-C₄)-alkynyloxy, (C₃-C₆)-cycloalkyl-(C₁-C₄)-alkyl or represents an optionally mono- or poly-M²-substituted C₃- to C₆-membered carbocyclic group; W represents oxygen; M¹ represents hydrogen, halogen, cyano, nitro, OH, (C₁-C₄)-alkyl, (C₁-C₄)-haloalkyl, (C₁-C₄)-alkoxy, (C₁-C₄)-haloalkoxy, (C₁-C₄)-alkylthio, (C₁-C₄)-haloalkylthio, (C₁-C₄)-alkylsulfonyl, (C₁-C₄)-haloalkylsulfonyl, (C₁-C₄)-alkylsulfanyl, (C₁-C₆)-haloalkylsulfanyl, (C₃-C₁₄)-cycloalkyl-O—, (C₃-C₁₄)-cycloalkenyl-O—, (C₆-C₁₄)-aryl-O—, halogenated (C₃-C₁₄)-cycloalkyl-O—, halogenated (C₃-C₁₄)-cycloalkenyl-O—, halogenated (C₆-C₁₄)-aryl-O—; R¹ represents hydrogen or methyl, ethyl, n-propyl, isopropyl, allyl, propargyl, cyclopropylmethyl or cyclopropyl; R¹¹, R¹² each independently of one another represent hydrogen, fluorine or (C₁-C₆)-alkyl, (C₁-C₆)-haloalkyl, (C₁-C₆)-alkoxy, (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl, (C₃-C₆)-cycloalkyl; R¹¹, R¹² represents C(R¹¹, R¹²) as spiro-C(CH₂—CH₂); R²¹, R²² each independently of one another represent hydrogen, fluorine or optionally mono- or poly-M²-substituted (C₁-C₄)-alkyl, (C₂-C₄)-alkenyl, (C₂-C₄)-alkynyl, (C₁-C₄)-haloalkyl, (C₁-C₆)-alkoxy, (C₂-C₄)-alkenyloxy, (C₃-C₄)-alkynyloxy, (C₃-C₄)-cycloalkyl-(C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl; R²¹, R²² represent C(R²¹, R²²) as spiro-C(CH₂—CH₂); R³¹, R³² each independently of one another represent hydrogen, methyl, ethyl, n-propyl, isopropyl, tert-butyl, allyl, propargyl, methoxy, ethoxy, allyloxy, propargyloxy, cyclopropylmethyl, cyclopropyl; R³¹, R³² represents C(R³¹, R³²) as spiro-C(CH₂—CH₂); M² each independently of one another represent chlorine, formyl, cyano, nitro, (C₁-C₄)-alkyl, (C₁-C₄)-haloalkyl, (C₁-C₄)-alkoxy, (C₁-C₄)-haloalkoxy, (C₁-C₄)-alkylthio, (C₁-C₄)-haloalkylthio, (C₁-C₄)-alkylsulfonyl, (C₁-C₄)-haloalkylsulfonyl, (C₁-C₄)-alkylsulfanyl, (C₁-C₄)-haloalkylsulfanyl, (C₁-C₄)-alkylcarbonyl, (C₁-C₄)-haloalkylcarbonyl or (C₃-C₆)-cycloalkyl; And/or a salt, N-oxide and/or tautomeric form thereof; capable of being used as medicament for controlling one or more endoparasites in an animal and/or human.
 4. The compound as claimed in any of claim 1 where Q represents 2-thienyl, 3-fluoro-2-thienyl, 3-chloro-2-thienyl, 3,4-dichloro-2-thienyl, 3,4,5-trichloro-2-thienyl, 3-bromo-2-thienyl, 3-iodo-2-thienyl, 3-cyano-2-thienyl, 3-methyl-2-thienyl, 3-(trifluoromethyl)-2-thienyl, 3-methoxy-2-thienyl, 3-ethoxy-2-thienyl, 3-thienyl, 2-fluoro-3-thienyl, 2-chloro-3-thienyl, 2-bromo-3-thienyl, 2-iodo-3-thienyl, 2-cyano-3-thienyl, 2-methyl-3-thienyl, 2-(trifluoromethyl)-3-thienyl, 2-methoxy-3-thienyl, 2-ethoxy-3-thienyl, 2-furanyl, 3-fluoro-2-furanyl, 3-chloro-2-furanyl, 3-bromo-2-furanyl, 3-iodo-2-furanyl, 3-cyano-2-furanyl, 3-methyl-2-furanyl, 3-(trifluoromethyl)-2-furanyl, 3-methoxy-2-furanyl, 3-ethoxy-2-furanyl, 3-furanyl, 2-chloro-3-furanyl, 2-bromo-3-furanyl, 2-iodo-3-furanyl, 2-cyano-3-furanyl, 2-methyl-3-furanyl, 2-(trifluoromethyl)-3-furanyl, 2-methoxy-3-furanyl, 2-ethoxy-3-furanyl, 4-chloro-5-isothiazolyl, 3,4-dichloro-5-isothiazolyl, 2-chloro-3-pyridyl, 3-chloro-2-pyridyl or 2-(trifluoromethyl)-3-pyridyl; Y represents hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, cyanomethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, allyl, butenyl, propargyl, butynyl, 3,3-dichloroprop-2-enyl, methoxy, ethoxy, cyclopropylmethyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; M¹ represents hydrogen, halogen, cyano, nitro, OH, (C₁-C₄)-alkyl, (C₁-C₄)-haloalkyl, (C₁-C₄)-alkoxy, (C₁-C₄)-haloalkoxy, (C₁-C₄)-alkylthio, (C₁-C₄)-haloalkylthio, (C₁-C₄)-alkylsulfonyl, (C₁-C₄)-haloalkylsulfonyl, (C₁-C₄)-alkylsulfanyl, (C₁-C₆)-haloalkylsulfanyl, (C₆-C₁₄)-aryl-O—, halogenated (C₆-C₁₄)-aryl)-O—; R¹ represents hydrogen or C₁-C₄-alkyl; R¹¹, R¹² each independently of one another represent hydrogen, fluorine, methyl, ethyl, n-propyl, isopropyl, allyl, propargyl, methoxy, ethoxy, allyloxy, propargyloxy, cyclopropylmethyl, cyclopropyl; R²¹, R²² each independently of one another represent hydrogen, fluorine, methyl, ethyl, n-propyl, isopropyl, allyl, propargyl, methoxy, ethoxy, allyloxy, propargyloxy, cyclopropylmethyl, cyclopropyl; R³¹, R³² each independently of one another represent hydrogen or (C₁-C₄)-alkyl; M² each independently of one another represent fluorine, bromine, chlorine, iodine, cyano, nitro, methyl, ethyl, isopropyl, tert-butyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, isopropoxy, trifluoromethoxy, difluoromethoxy, methylthio, trifluoromethylthio, difluoromethylthio, 2,2,2-trifluoroethylthio, methylsulfonyl, ethylsulfonyl, trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, methylsulfanyl, ethylsulfanyl, trifluoromethylsulfanyl, 2,2,2-trifluoroethylsulfanyl, cyclopropyl, cyclobutyl or cyclopentyl. And/or a salt, N-oxide and/or tautomeric form thereof; capable of being used as medicament for controlling one or more endoparasites in an animal and/or human.
 5. A compound of the formula (I-b)

in which X represents mono- or poly-M¹-substituted phenyl, thienyl or furanyl; Q represents mono- or poly-M¹-substituted pyridyl, thienyl, furanyl or isothiazolyl; Y represents hydrogen or represents optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₂-C₁₀)-alkenyloxy, (C₃-C₁₀)-alkynyloxy, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represents an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; W represents oxygen or sulfur; L¹ represents —C(R¹¹, R¹²)—, oxygen, sulfur or —N(R¹)—; L² represents —C(R²¹, R²²)—; L³ represents —C(R³¹, R³²)— or a direct bond; R¹ represents hydrogen or optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₃-C₁₀)-cycloalkyl-(C₁-C₁₀)-alkyl or represents an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; R¹¹, R¹² each independently of one another represent hydrogen, halogen or optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₂-C₁₀)-alkenyloxy, (C₃-C₁₀)-alkynyloxy, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represents an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; R¹¹, R¹² together represent an optionally mono- or poly-M²-substituted spiro-attached 3- to 14-membered carbo- or 3- to 10-membered heterocyclic group; R²¹, R²² each independently of one another represent hydrogen, halogen or optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-haloalkoxy, (C₂-C₁₀)-alkenyloxy, (C₃-C₁₀)-alkynyloxy, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represent an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; R²¹, R²² together represent an optionally mono- or poly-M²-substituted spiro-attached 3- to 14-membered carbo- or 3- to 10-membered heterocyclic group; R³¹, R³² each independently of one another represent hydrogen or optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represent an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; R³¹, R³² together represent an optionally mono- or poly-M²-substituted spiro-attached 3- to 14-membered carbo- or 3- to 10-membered heterocyclic group; M² each independently of one another represent halogen, formyl, cyano, nitro, (C₁-C₁₀)-alkyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-alkynyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-haloalkoxy, (C₂-C₁₀)-alkenyloxy, (C₂-C₁₀)-haloalkenyloxy, (C₃-C₁₀)-alkynyloxy, (C₃-C₁₀)-haloalkynyloxy, (C₁-C₁₀)-alkylthio, (C₁-C₁₀)-haloalkylthio, (C₂-C₁₀)-alkenylthio, (C₂-C₁₀)-haloalkenylthio, (C₃-C₁₀)-alkynylthio, (C₃-C₁₀)-haloalkynylthio, (C₁-C₁₀)-alkylsulfonyl, (C₁-C₁₀)-haloalkylsulfonyl, (C₂-C₁₀)-alkenylsulfonyl, (C₂-C₁₀)-haloalkenylsulfonyl, (C₃-C₁₀)-alkynylsulfonyl, (C₃-C₁₀)-haloalkynylsulfonyl, (C₁-C₁₀)-alkylsulfanyl, (C₁-C₁₀)-haloalkylsulfanyl, (C₂-C₁₀)-alkenylsulfanyl, (C₂-C₁₀)-haloalkenylsulfanyl, (C₃-C₁₀)-alkynylsulfanyl, (C₃-C₁₀)-haloalkynylsulfanyl, (C₁-C₁₀)-alkylcarbonyl, (C₁-C₁₀)-haloalkylcarbonyl, (C₂-C₁₀)-alkenylcarbonyl, (C₂-C₁₀)-haloalkenylcarbonyl, (C₂-C₁₀)-alkynylcarbonyl, (C₂-C₁₀)-haloalkynylcarbonyl, (C₁-C₁₀)-alkoxycarbonyl, (C₁-C₁₀)-haloalkoxycarbonyl, (C₂-C₁₀)-alkenyloxycarbonyl, (C₂-C₁₀)-haloalkenyloxycarbonyl, (C₃-C₁₀)-alkynyloxycarbonyl, (C₃-C₁₀)-haloalkynyloxycarbonyl, (C₁-C₁₀)-alkylcarbonyloxy, (C₁-C₁₀)-haloalkylcarbonyloxy, (C₂-C₁₀)-alkenylcarbonyloxy, (C₂-C₁₀)-haloalkenylcarbonyloxy, (C₂-C₁₀)-alkynylcarbonyloxy, (C₂-C₁₀)-haloalkynylcarbonyloxy, a 3- to 14-membered cyclic group; M¹ and M³ independently of one another represent halogen, cyano, nitro, OH, (C₁-C₁₀)-alkyl, (C₁-C₁₀)-haloalkyl, (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-haloalkoxy, (C₁-C₁₀)-alkylthio, (C₁-C₁₀)-haloalkylthio, (C₁-C₁₀)-alkylsulfonyl, (C₁-C₁₀)-haloalkylsulfonyl, (C₁-C₁₀)-alkylsulfanyl, (C₁-C₁₀)-haloalkylsulfanyl, (3- to 14-membered cyclic group)-O—; n represents an integer from 0 to 4; And/or a salt, N-oxide and/or tautomeric form thereof; capable of being used as medicament for controlling one or more endoparasites in an animal and/or human.
 6. A Compound of formula (I)

in which X represents mono- or poly-M¹-substituted phenyl, thienyl or furanyl; Y represents hydrogen or represents optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₂-C₁₀)-alkenyloxy, (C₃-C₁₀)-alkynyloxy, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represents an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; W represents oxygen or sulfur; L¹ represents —C(R¹¹, R¹²)—, oxygen, sulfur or —N(R¹)—; L² represents —C(R²¹, R²²)—; M¹ represents hydrogen, halogen, cyano, nitro, OH, (C₁-C₁₀)-alkyl, (C₁-C₁₀)-haloalkyl, (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-haloalkoxy, (C₁-C₁₀)-alkylthio, (C₁-C₁₀)-haloalkylthio, (C₁-C₁₀)-alkylsulfonyl, (C₁-C₁₀)-haloalkylsulfonyl, (C₁-C₁₀)-alkylsulfanyl, (C₁-C₁₀)-haloalkylsulfanyl, (3- to 14-membered cyclic group)-O—; R¹ represents hydrogen or optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₃-C₁₀)-cycloalkyl-(C₁-C₁₀)-alkyl or represents an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; R¹¹, R¹² each independently of one another represent hydrogen, halogen or optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₂-C₁₀)-alkenyloxy, (C₃-C₁₀)-alkynyloxy, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represents an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; R¹¹, R¹² together represent an optionally mono- or poly-M²-substituted spiro-attached 3- to 14-membered carbo- or 3- to 10-membered heterocyclic group; R³¹, R²² each independently of one another represent hydrogen, halogen or optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-haloalkoxy, (C₂-C₁₀)-alkenyloxy, (C₃-C₁₀)-alkynyloxy, (C₃-C₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represent an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; R²¹, R²² together represent an optionally mono- or poly-M²-substituted spiro-attached 3- to 14-membered carbo- or 3- to 10-membered heterocyclic group; R³¹, R³² each independently of one another represent hydrogen or optionally mono- or poly-M²-substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-haloalkynyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₁₀)-alkyl or represent an optionally mono- or poly-M²-substituted 3- to 14-membered cyclic group; R³¹, R³² together represent an optionally mono- or poly-M²-substituted spiro-attached 3- to 14-membered carbo- or 3- to 10-membered heterocyclic group; M² each independently of one another represent halogen, formyl, cyano, nitro, (C₁-C₁₀)-alkyl, (C₁-C₁₀)-haloalkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-haloalkenyl, (C₂-C₁₀)-alkynyl, (C₂-C₁₀)-haloalkynyl, (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-haloalkoxy, (C₂-C₁₀)-alkenyloxy, (C₂-C₁₀)-haloalkenyloxy, (C₃-C₁₀)-alkynyloxy, (C₃-C₁₀)-haloalkynyloxy, (C₁-C₁₀)-alkylthio, (C₁-C₁₀)-haloalkylthio, (C₂-C₁₀)-alkenylthio, (C₂-C₁₀)-haloalkenylthio, (C₃-C₁₀)-alkynylthio, (C₃-C₁₀)-haloalkynylthio, (C₁-C₁₀)-alkylsulfonyl, (C₁-C₁₀)-haloalkylsulfonyl, (C₂-C₁₀)-alkenylsulfonyl, (C₂-C₁₀)-haloalkenylsulfonyl, (C₃-C₁₀)-alkynylsulfonyl, (C₃-C₁₀)-haloalkynylsulfonyl, (C₁-C₁₀)-alkylsulfanyl, (C₁-C₁₀)-haloalkylsulfanyl, (C₂-C₁₀)-alkenylsulfanyl, (C₂-C₁₀)-haloalkenylsulfanyl, (C₃-C₁₀)-alkynylsulfanyl, (C₃-C₁₀)-haloalkynylsulfanyl, (C₁-C₁₀)-alkylcarbonyl, (C₁-C₁₀)-haloalkylcarbonyl, (C₂-C₁₀)-alkenylcarbonyl, (C₂-C₁₀)-haloalkenylcarbonyl, (C₂-C₁₀)-alkynylcarbonyl, (C₂-C₁₀)-haloalkynylcarbonyl, (C₁-C₁₀)-alkoxycarbonyl, (C₁-C₁₀)-haloalkoxycarbonyl, (C₂-C₁₀)-alkenyloxycarbonyl, (C₂-C₁₀)-haloalkenyloxycarbonyl, (C₃-C₁₀)-alkynyloxycarbonyl, (C₃-C₁₀)-haloalkynyloxycarbonyl, (C₁-C₁₀)-alkylcarbonyloxy, (C₁-C₁₀)-haloalkylcarbonyloxy, (C₂-C₁₀)-alkenylcarbonyloxy, (C₂-C₁₀)-haloalkenylcarbonyloxy, (C₂-C₁₀)-alkynylcarbonyloxy, (C₂-C₁₀)-haloalkynylcarbonyloxy, a 3- to 14-membered cyclic group; Q represents a mono- or poly-M¹-substituted phenyl where the phenyl may not be substituted by trifluoromethyl in the 2-position; L³ represents C(R³¹, R³²) where R³¹ and R³² each independently of one another represent hydrogen, methyl, ethyl, n-propyl, isopropyl, allyl, propargyl, methoxy, ethoxy, allyloxy, propargyloxy, cyclopropylmethyl, cyclopropyl; And/or a salt, N-oxide and/or tautomeric form thereof; capable of being used as medicament for controlling one or more endoparasites in an animal and/or human.
 7. The compound of formula (I) according to claim 1,

in which L², L³, M¹, W, X and Y are as defined in claim 1 and Q represents a mono- or poly-M¹-substituted phenyl; L¹ represents —N(R¹) where R¹ represents hydrogen or optionally mono- or poly-M²-substituted (C₁-C₄)-alkyl, (C₃-C₄)-alkenyl, (C₃-C₄)-alkynyl, (C₁-C₄)-haloalkyl, (C₃-C₄)-haloalkenyl, (C₃-C₄)-haloalkynyl, (C₃-C₆)-cycloalkyl-(C₁-C₄)-alkyl or represent an optionally substituted C₃- to C₆-membered carbocyclic group; L¹ represents sulfur; or L¹ represents —C(R¹¹, R¹²)— where R¹¹, R¹² each independently of one another represent halogen, (C₁-C₆)-haloalkyl or (C₁-C₆)-alkoxy; And/or a salt, N-oxide and/or tautomeric form thereof; capable of being used as medicament for controlling one or more endoparasites in an animal and/or human.
 8. A compound as claimed in claim 1 capable of being used for preparing a medicament for controlling one or more endoparasites in an animal and/or human.
 9. The compound as claimed in claim 1 capable of being used control of one or more endoparasites in an animal and/or human by a method comprising prophylactically and/or therapeutically administering, the compound and/or salt, N-oxide and/or tautomeric form to an animal and/or human.
 10. An endoparasiticidal composition comprising a compound as claimed in claim
 1. 